Document_And_Entity_Informatio
Document And Entity Information (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Mar. 28, 2014 | Jun. 28, 2013 | |
Document Information [Line Items] | ' | ' | ' |
Entity Registrant Name | 'AMERICAN BIO MEDICA CORP | ' | ' |
Entity Central Index Key | '0000896747 | ' | ' |
Current Fiscal Year End Date | '--12-31 | ' | ' |
Entity Filer Category | 'Smaller Reporting Company | ' | ' |
Trading Symbol | 'ABMC | ' | ' |
Entity Common Stock, Shares Outstanding | ' | 23,168,155 | ' |
Document Type | '10-K | ' | ' |
Amendment Flag | 'false | ' | ' |
Document Period End Date | 31-Dec-13 | ' | ' |
Document Fiscal Period Focus | 'FY | ' | ' |
Document Fiscal Year Focus | '2013 | ' | ' |
Entity Well-known Seasoned Issuer | 'No | ' | ' |
Entity Voluntary Filers | 'No | ' | ' |
Entity Current Reporting Status | 'Yes | ' | ' |
Entity Public Float | ' | ' | $2,762,000 |
Balance_Sheets
Balance Sheets (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Current assets | ' | ' |
Cash and cash equivalents | $646,000 | $89,000 |
Accounts receivable, net of allowance for doubtful accounts of $58,000 at December 31, 2013 and $60,000 at December 31, 2012 | 875,000 | 810,000 |
Inventory, net of allowance of $399,000 at December 31, 2013 and $261,000 at December 31, 2012 | 2,071,000 | 2,571,000 |
Current portion of deferred financing | 51,000 | 0 |
Prepaid expenses and other current assets | 96,000 | 50,000 |
Total current assets | 3,739,000 | 3,520,000 |
Property, plant and equipment, net | 1,090,000 | 1,192,000 |
Deferred finance costs | 80,000 | 29,000 |
Patents, net | 43,000 | 24,000 |
Other assets | 14,000 | 14,000 |
Total assets | 4,966,000 | 4,779,000 |
Current liabilities | ' | ' |
Accounts payable | 597,000 | 1,016,000 |
Accrued expenses and other current liabilities | 314,000 | 174,000 |
Wages payable | 233,000 | 231,000 |
Line of credit, net | 987,000 | 321,000 |
Current portion of long-term debt, net | 1,226,000 | 1,404,000 |
Total current liabilities | 3,357,000 | 3,146,000 |
Other liabilities | 147,000 | 145,000 |
Related party note | 124,000 | 124,000 |
Total liabilities | 3,628,000 | 3,415,000 |
COMMITMENTS AND CONTINGENCIES | ' | ' |
Stockholders' equity: | ' | ' |
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at December 31, 2013 and 2012 | ' | ' |
Common stock; par value $.01 per share; 50,000,000 shares authorized; 22,959,822 issued and outstanding as of December 31, 2013 and 21,833,003 issued and outstanding at December 31, 2012 | 229,000 | 218,000 |
Additional paid-in capital | 20,241,000 | 19,490,000 |
Accumulated deficit | -19,132,000 | -18,344,000 |
Total stockholders' equity | 1,338,000 | 1,364,000 |
Total liabilities and stockholders' equity | $4,966,000 | $4,779,000 |
Balance_Sheets_Parenthetical
Balance Sheets (Parenthetical) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Accounts receivable, net of allowance for doubtful accounts (in dollars) | $58,000 | $60,000 |
Inventory, net of allowance for slow moving and obsolete inventory (in dollars) | $399,000 | $261,000 |
Preferred stock, par value (in dollars per share) | $0.01 | $0.01 |
Preferred stock, shares authorized | 5,000,000 | 5,000,000 |
Preferred stock, shares issued | 0 | 0 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value (in dollars per share) | $0.01 | $0.01 |
Common stock, shares authorized | 50,000,000 | 50,000,000 |
Common stock, shares issued | 22,959,822 | 21,833,003 |
Common stock, shares outstanding | 22,959,822 | 21,833,003 |
Statements_of_Operations
Statements of Operations (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Net sales | $8,894,000 | $9,343,000 |
Cost of goods sold | 5,322,000 | 5,999,000 |
Gross profit | 3,572,000 | 3,344,000 |
Operating expenses: | ' | ' |
Research and development | 645,000 | 207,000 |
Selling and marketing | 1,722,000 | 1,829,000 |
General and administrative | 2,336,000 | 2,237,000 |
Operating loss | -1,131,000 | -929,000 |
Other income / (expense): | ' | ' |
Interest income | 2,000 | 1,000 |
Interest expense | -310,000 | -194,000 |
Other income, net | 653,000 | 9,000 |
Net loss before tax | -786,000 | -1,113,000 |
Income tax benefit (expense) | -2,000 | 2,000 |
Net loss | ($788,000) | ($1,111,000) |
Basic and diluted loss per common share (in dollars per share) | ($0.04) | ($0.05) |
Weighted average number of shares outstanding - basic and diluted (in shares) | 22,270,636 | 21,833,003 |
Statements_of_Changes_in_Stock
Statements of Changes in Stockholders’ Equity (USD $) | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] |
Balance at Dec. 31, 2011 | $2,370,000 | $217,000 | $19,386,000 | ($17,233,000) |
Balance (in shares) at Dec. 31, 2011 | ' | 21,744,768 | ' | ' |
Shares issued in connection with bridge loan | 1,000 | 1,000 | ' | ' |
Shares issued in connection with bridge loan (in shares) | ' | 88,235 | ' | ' |
Share based payment expense | 104,000 | ' | 104,000 | ' |
Net loss | -1,111,000 | ' | ' | -1,111,000 |
Balance at Dec. 31, 2012 | 1,364,000 | 218,000 | 19,490,000 | -18,344,000 |
Balance (in shares) at Dec. 31, 2012 | ' | 21,833,003 | ' | ' |
Shares issued in connection with Monarch consulting agreement | 86,000 | 3,000 | 83,000 | ' |
Shares issued in connection with Monarch consulting agreement (in shares) | ' | 333,333 | ' | ' |
Shares issued in connection with Series A Debenture extension | 102,000 | 8,000 | 94,000 | ' |
Shares issued in connection with Series A Debenture extension (in shares) | ' | 793,486 | ' | ' |
Warrants issued in connection with Imperium line of credit | 299,000 | ' | 299,000 | ' |
Warrants issued in connection with Series A Debenture extension | 121,000 | ' | 121,000 | ' |
Share based payment expense | 154,000 | ' | 154,000 | ' |
Net loss | -788,000 | ' | ' | -788,000 |
Balance at Dec. 31, 2013 | $1,338,000 | $229,000 | $20,241,000 | ($19,132,000) |
Balance (in shares) at Dec. 31, 2013 | ' | 22,959,822 | ' | ' |
Statements_of_Cash_Flows
Statements of Cash Flows (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Cash flows from operating activities: | ' | ' |
Net loss | ($788,000) | ($1,111,000) |
Adjustments to reconcile net loss to net cash provided by / (used in) operating activities: | ' | ' |
Depreciation | 116,000 | 123,000 |
Amortization of debt issuance costs | 267,000 | 47,000 |
Provision for bad debts | -4,000 | -6,000 |
Provision for slow moving and obsolete inventory | 138,000 | 454,000 |
Share-based payment expense | 257,000 | 104,000 |
Changes in: | ' | ' |
Accounts receivable | -63,000 | 79,000 |
Inventory | 363,000 | 214,000 |
Prepaid expenses and other current assets | -21,000 | 11,000 |
Other assets | 0 | 15,000 |
Accounts payable | -420,000 | 386,000 |
Accrued expenses and other current liabilities | 162,000 | -38,000 |
Unearned grant | 0 | -10,000 |
Wages payable | 2,000 | -34,000 |
Other liabilities | 0 | 2,000 |
Net cash provided by operating activities | 9,000 | 236,000 |
Cash flows from investing activities: | ' | ' |
Purchase of property, plant and equipment | -14,000 | -11,000 |
Patent application costs | -20,000 | -23,000 |
Net cash provided by / (used in) investing activities | -34,000 | -34,000 |
Cash flows from financing activities: | ' | ' |
Proceeds from lines of credit | 10,142,000 | 10,185,000 |
Payments on lines of credit | -9,220,000 | -10,261,000 |
Debt issuance costs | -161,000 | -50,000 |
Proceeds from bridge loan | 50,000 | 150,000 |
Payments on debt financing | -229,000 | -230,000 |
Net cash provided by / (used in) financing activities | 582,000 | -206,000 |
Net (decrease) / increase in cash and cash equivalents | 557,000 | -4,000 |
Cash and cash equivalents - beginning of period | 89,000 | 93,000 |
Cash and cash equivalents - end of period | 646,000 | 89,000 |
Supplemental disclosures of cash flow information: | ' | ' |
Cash paid during the year for interest | $456,000 | $201,000 |
The_Company_and_its_Significan
The Company and its Significant Accounting Policies | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Accounting Policies [Abstract] | ' | |||||||
Basis of Presentation and Significant Accounting Policies [Text Block] | ' | |||||||
Note A - The Company and its Significant Accounting Policies | ||||||||
The Company: | ||||||||
American Bio Medica Corporation (the “Company”) is in the business of developing, manufacturing, and marketing point of collection testing products for drugs of abuse, as well as performing contract manufacturing services for third parties. | ||||||||
The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and the satisfaction of liabilities in the normal course of business. For the year ended December 31, 2013 (“Fiscal 2013”), the Company had a net loss of $788,000 and net cash provided by operating activities of $9,000, compared to a net loss of $1,111,000 and net cash provided by operating activities of $236,000 for the year ended December 31, 2012 (“Fiscal 2012”). The Company’s cash balances increased $557,000 during Fiscal 2013 and decreased by $4,000 during Fiscal 2012. | ||||||||
As of December 31, 2013, the Company had an accumulated deficit of $19,132,000. In August 2013, the Company implemented a number of expense and personnel cuts, and implemented a salary and commission deferral program. The salary deferral program consists of a 20% salary deferral for our 2 (then) executive officers (Stan Cipkowski and Melissa Waterhouse) as well as a 20% salary deferral for our non-executive VP Operations, Douglas Casterlin and a sales consultant. The commission deferral program consists of a 50% commission deferral of employee commissions. As of December 31, 2013, we have deferred salary compensation owed of $19,000 and deferred commision owed of $52,000. In January 2014, the Company did repay a small portion of the deferrals (approximately $31,000), however the deferral program is continuing and the Company expects it will continue for up to 12 months. The Company continues to analyze and control expenses, product costs, inventory levels and other measures to enhance profit margins. | ||||||||
If cash generated from operations is insufficient to satisfy the Company’s working capital and capital expenditure requirements, the Company will be required to sell additional equity or obtain additional credit facilities. On August 1, 2014, the Series A Debentures will mature (See Note E – Long Term Debt). On the maturity date, the Company is obligated to pay all principal and interest due (approximately $544,000 as we paid back $91,000 to 2 debenture holders in February 2014 that only extended their debentures for 6 months) to the Holders of the Series A Debentures. In addition, principal on the Bridge Loan from Cantone Asset Management LLC (“CAM”), or $200,000, will become due on August 1, 2014. And finally, the Company’s Mortgage Consolidation Loan with First Niagara Bank has a maturity date of March 1, 2014 and all principal and interest will become due upon maturity (See Note L – Subsequent Event). The Company is currently looking at alternatives to refinance the amounts due to the Series A Debenture Holders and to CAM. There can be no assurance, however, that such financing will be available or that the Company will be able to complete financing on satisfactory terms, if at all. | ||||||||
The Company’s ability to repay or to refinance its current debt will depend primarily upon its future operating performance, which may be affected by general economic, financial, competitive, regulatory, business and other factors beyond its control, including those discussed herein. In addition, the Company cannot assure you that future borrowings or equity financing will be available for the payment or refinancing of any indebtedness the Company may have. | ||||||||
The Company’s failure to comply with the restrictive covenants under its revolving credit facility and other debt instruments could result in an event of default, which, if not cured or waived, could result in the Company being required to repay these borrowings before their due date or pay higher costs associated with the indebtedness. If the Company is forced to refinance these borrowings on less favorable terms, its results of operations and financial condition could be adversely affected by increased costs and rates. The Company may also be forced to pursue one or more alternative strategies, such as restructuring or refinancing its indebtedness, selling assets, reducing or delaying capital expenditures or seeking additional equity capital. There can be no assurances that any of these strategies could be effected on satisfactory terms, if at all. | ||||||||
The Company’s history of operating cash flow deficits, its current cash position and lack of access to capital raise substantial doubt about its ability to continue as a going concern and its continued existence is dependent upon several factors, including its ability to raise revenue levels and reduce costs to generate positive cash flows, to sell additional shares of the Company’s common stock to fund operations and obtain additional credit facilities. Selling additional shares of the Company’s common stock and obtaining additional credit facilities may be more difficult as a result of limited access to equity markets and the tightening of credit markets. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount of or classification of liabilities that might be necessary as a result of this uncertainty. | ||||||||
Significant Accounting Policies: | ||||||||
[1] Cash equivalents: The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. | ||||||||
[2] Accounts Receivable: Accounts receivable consists of mainly trade receivables due from customers for the sale of our products. Payment terms vary on a customer-by-customer basis, and currently range from cash on delivery to net 60 days. Receivables are considered past due when they have exceeded their payment terms. Accounts receivable have been reduced by an estimated allowance for doubtful accounts. The Company estimates its allowance for doubtful accounts based on facts, circumstances and judgments regarding each receivable. Customer payment history and patterns, historical losses, economic and political conditions, trends and individual circumstances are among the items considered when evaluating the collectability of the receivables. Accounts are reviewed regularly for collectability and those deemed uncollectible are written off. At December 31, 2013 and December 31, 2012 the Company had an allowance for doubtful accounts of $58,000 and $60,000, respectively. | ||||||||
[3] Inventory: Inventory is stated at the lower of cost or market. Work in process and finished goods are comprised of labor, overhead and raw material costs. Labor and overhead costs are determined on a rolling average cost basis and raw materials are determined on an average cost basis. At December 31, 2013 and December 31, 2012, the Company established an allowance for slow moving and obsolete inventory of $399,000 and $261,000, respectively. | ||||||||
[4] Income taxes: The Company follows ASC 740 “Income Taxes” (“ASC 740”) which prescribes the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted laws and tax rates that will be in effect when the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits that are not expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. Under ASC 740, tax benefits are recorded only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon ultimate settlement. Unrecognized tax benefits are tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. | ||||||||
[5] Depreciation and amortization: Property, plant and equipment are depreciated on the straight-line method over their estimated useful lives; generally 3-5 years for equipment and 30 years for buildings. Leasehold improvements and capitalized lease assets are amortized by the straight-line method over the shorter of their estimated useful lives or the term of the lease. Intangible assets include the cost of patent applications, which are deferred and charged to operations over 19 years. The accumulated amortization of patents is $158,000 and $156,000 at December 31, 2013 and December 31, 2012, respectively. Annual amortization expense of such intangible assets is expected to be $2,000 per year for the next 5 years. | ||||||||
[6] Revenue recognition: The Company recognizes revenue when title transfers upon shipment. Sales are recorded net of discounts and returns. All buyers have economic substance apart from the Company and the Company does not have any obligation for customer acceptance. The Company's price is fixed and determinable at the date of sale. The buyer has paid the Company or is obligated to pay the Company or, in the case of a distributor, the obligation is not contingent on the resale of the product, nor does the Company have any obligation to bring about the resale of the product. The buyer's obligation would not be changed in the event of theft or physical destruction or damage to the product. All distributors have economic substance apart from the Company and their own customers and payment terms are not conditional. The transactions with distributors are on terms similar to those given to the Company's other customers. No agreements exist with the distributors that offer a right of return. | ||||||||
[7] Shipping and handling: Shipping and handling fees charged to customers are included in net sales, and shipping and handling costs incurred by the Company, to the extent of those costs charged to customers, are included in cost of sales. | ||||||||
[8] Research and development: Research and development (“R&D”) costs are charged to operations when incurred. These costs include salaries, benefits, travel, supplies, depreciation of R&D equipment and other miscellaneous expenses. | ||||||||
[9] Net loss per common share: Basic loss per common share is calculated by dividing net loss by the weighted average number of outstanding common shares during the period. | ||||||||
Potential common shares outstanding as of December 31, 2013 and 2012: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
Warrants | 3,303,000 | 375,000 | ||||||
Options | 3,316,000 | 2,939,000 | ||||||
For Fiscal 2013 and Fiscal 2012, the number of securities not included in the diluted loss per share was 6,619,000 and 3,314,000, respectively, as their effect was anti-dilutive. | ||||||||
[10] Use of estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our management believes the major estimates and assumptions impacting our financial statements are the following: | ||||||||
⋅ | estimates of the fair value of stock options and warrants at date of grant; and | |||||||
⋅ | estimates of the inventory reserves; and | |||||||
⋅ | estimates and evaluation of litigation being pursued. | |||||||
The fair value of stock options and warrants issued to employees, members of our Board of Directors, consultants and in connection with debt financings is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk free interest rate; volatility; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. | ||||||||
As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company's forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. | ||||||||
If the Company's actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the equity-based compensation expense could be significantly different from what we have recorded in the current period. | ||||||||
Actual results may differ from estimates and assumptions of future events. | ||||||||
[11] Impairment of long-lived assets: The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. | ||||||||
[12] Financial Instruments: The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and other liabilities approximate their fair value based on the short term nature of those items. | ||||||||
Estimated fair value of financial instruments is determined using available market information. In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. | ||||||||
Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. | ||||||||
ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC Topic 820”) establishes a hierarchy for ranking the quality and reliability of the information used to determine fair values. ASC Topic 820 requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: | ||||||||
Level 1: Unadjusted quoted market prices in active markets for identical assets or liabilities. | ||||||||
Level 2: Unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices are observable for the asset or liability. | ||||||||
Level 3: Unobservable inputs for the asset or liability. | ||||||||
The Company endeavors to utilize the best available information in measuring fair value. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments: | ||||||||
Cash and Cash Equivalents—The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair value due to the short-term maturity of these instruments. | ||||||||
Line of Credit and Long-Term Debt—The carrying amounts of the Company’s borrowings under its line of credit agreement and other long-term debt approximates fair value, based upon current interest rates, some of which are variable interest rates. | ||||||||
[13] Accounting for share-based payments and stock warrants: In accordance with the provisions of ASC Topic 718, “Accounting for Stock Based Compensation”, the Company recognizes share-based payment expense for stock options and warrants. The weighted average fair value of options granted during Fiscal 2013 and Fiscal 2012 was $0.13 and $0.18, respectively. (See Note I [2] – Stockholders’ Equity) | ||||||||
The Company accounts for derivative instruments in accordance with ASC Topic 815 “Derivatives and Hedging” (“ASC Topic 815”). The guidance within ASC Topic 815 requires the Company to recognize all derivatives as either assets or liabilities on the statement of financial position unless the contract, including common stock warrants, settles in the Company’s own stock and qualifies as an equity instrument. A contract designated as an equity instrument is included in equity at its fair value, with no further fair value adjustments required; and if designated as an asset or liability is carried at fair value with any changes in fair value recorded in the results of operations. The weighted average fair value of warrants issued was $0.17 in Fiscal 2013 and $0.16 in Fiscal 2012. (See Note I [3] – Stockholders’ Equity) | ||||||||
[14] Concentration of credit risk: The Company sells its drug-testing products primarily to United States customers and distributors. Credit is extended based on an evaluation of the customer’s financial condition. | ||||||||
At December 31, 2013, one customer accounted for 39.7% of the Company’s net accounts receivable. A substantial portion of this balance was collected in the first quarter of the year ending December 31, 2014. Due to the longstanding nature of our relationships with these customers and contractual obligations, the Company is confident that it will recover these amounts. | ||||||||
At December 31, 2012, three customers accounted for 12.8%, 9.7% and 9.6% of the Company’s net accounts receivable. A substantial portion of these balances was collected in the first quarter of the year ending December 31, 2013. Due to the longstanding nature of our relationships with these customers and contractual obligations, the Company is confident that it will recover these amounts. | ||||||||
The Company has established an allowance for doubtful accounts of $58,000 and $60,000 at December 31, 2013 and December 31, 2012, respectively, based on factors surrounding the credit risk of our customers and other information. | ||||||||
One of the Company’s customers accounted for approximately 15.5% of net sales of the Company in Fiscal 2013 and 14.8% of net sales of the Company in Fiscal 2012. | ||||||||
The Company maintains certain cash balances at financial institutions that are federally insured and at times the balances have exceeded federally insured limits. | ||||||||
[15] Reporting comprehensive income: The Company reports comprehensive income in accordance with the provisions of ASC Topic 220, “Reporting Comprehensive Income” (“ASC Topic 220”). The provisions of ASC Topic 220 require the Company to report the change in the Company's equity during the period from transactions and events other than those resulting from investments by, and distributions to, the shareholders. For Fiscal 2013 and Fiscal 2012, comprehensive income was the same as net income. | ||||||||
[16] Reclassifications: Certain items have been reclassified from the prior years to conform to the current year presentation. | ||||||||
[17] New accounting pronouncements: There were no new standards adopted in Fiscal 2013 that materially impacted the Company’s financial statements. | ||||||||
INVENTORY
INVENTORY | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Inventory Disclosure [Abstract] | ' | |||||||
Inventory Disclosure [Text Block] | ' | |||||||
NOTE B - INVENTORY | ||||||||
Inventory is comprised of the following: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
Raw Materials | $ | 1,434,000 | $ | 1,578,000 | ||||
Work In Process | 758,000 | 671,000 | ||||||
Finished Goods | 278,000 | 583,000 | ||||||
Allowance for slow moving and obsolete inventory | -399,000 | -261,000 | ||||||
$ | 2,071,000 | $ | 2,571,000 | |||||
PROPERTY_PLANT_AND_EQUIPMENT
PROPERTY, PLANT AND EQUIPMENT | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Property, Plant and Equipment [Abstract] | ' | |||||||
Property, Plant and Equipment Disclosure [Text Block] | ' | |||||||
NOTE C – PROPERTY, PLANT AND EQUIPMENT | ||||||||
Property, plant and equipment, at cost, are as follows: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
Land | $ | 102,000 | $ | 102,000 | ||||
Buildings and improvements | 1,363,000 | 1,363,000 | ||||||
Manufacturing and warehouse equipment | 2,601,000 | 2,589,000 | ||||||
Office equipment (incl. furniture and fixtures) | 412,000 | 409,000 | ||||||
4,478,000 | 4,463,000 | |||||||
Less accumulated depreciation | -3,388,000 | -3,271,000 | ||||||
$ | 1,090,000 | $ | 1,192,000 | |||||
Depreciation expense was $116,000 and $123,000 Fiscal 2013 and Fiscal 2012, respectively. | ||||||||
ACCRUED_EXPENSES_AND_OTHER_CUR
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Payables and Accruals [Abstract] | ' | |||||||
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] | ' | |||||||
NOTE D – ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES | ||||||||
Accrued expenses and other current liabilities consisted of the following: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
Accrued accounting fees | $ | 65,000 | $ | 40,000 | ||||
Accrued interest payable | 35,000 | 29,000 | ||||||
Accounts receivable credit balances | 24,000 | 27,000 | ||||||
Accrued sales tax payable | 89,000 | 42,000 | ||||||
Accrued expenses | 26,000 | 24,000 | ||||||
Other current liabilities | 75,000 | 12,000 | ||||||
$ | 314,000 | $ | 174,000 | |||||
LONGTERM_DEBT
LONG-TERM DEBT | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Debt Disclosure [Abstract] | ' | |||||||
Long-term Debt [Text Block] | ' | |||||||
NOTE E – LONG-TERM DEBT | ||||||||
Long-term debt consisted of the following: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
First Niagara: | ||||||||
Mortgage payable in equal monthly installments of $14,000 including interest at 9.25% through March 1, 2014 (“Maturity”) with a final lump sum payment representing the entire unpaid balance of principal, plus accrued interest at Maturity, collateralized by the building, land and personal property(1) | $ | 452,000 | $ | 608,000 | ||||
MARLIN: | ||||||||
Capital lease payable in equal monthly installment of $147 including interest at 14.46% through September 1, 2013 | 0 | 1,000 | ||||||
Debenture financing(2): | ||||||||
$634,000 in principal amount of Series A Debentures; interest at 15% per annum from August 1, 2013 through August 1, 2014, payable quarterly with first payment due November 1, 2013; maturity date of August 1, 2014 | 634,000 | 645,000 | ||||||
Bridge Loan with Cantone Asset Management, LLC(3): | ||||||||
Interest rate of 15% payable upon loan maturity; maturity date of August 1, 2014. | 200,000 | 150,000 | ||||||
1,286,000 | 1,404,000 | |||||||
Less debt discount (Debenture financing) | -60,000 | 0 | ||||||
Total current debt | $ | 1,226,000 | $ | 1,404,000 | ||||
-1 | The mortgage through First Niagara was refinanced and extended on March 8, 2013. | |||||||
-2 | The original debt with the Series A Debenture Holders was $750,000, with an interest rate of 10% per annum. It was payable semi-annually in August and February of each year with the first payment due February 1, 2009 and a maturity date of August 1, 2012. In July 2012, the Series A Debentures were amended and extended; under the amendment and extension the interest rate from August 1, 2012 through December 31, 2012 was increased to 15% per annum (the interest rate from January 1, 2012 through July 31, 2012 remained at 10%), and the maturity date was extended to August 1, 2013, and $105,000 of Series A Debentures were repaid with a portion of loan proceeds from Cantone Asset Management LLC; lowering the principal of the Series A Debenture to $645,000. The Series A Debentures were amended and extended in October 2013, and the terms noted in the table above are the revised terms of the Series A Debentures. $10,000 in Series A Debentures was repaid under the extension, lowering the principal to $635,000 at December 31, 2013. Even after the amendment and extension, the Series A Debentures remained classified as a current liability given their maturity date of August 1, 2014. | |||||||
-3 | In October 2013, the Company increased our Bridge Loan with Cantone Asset Management LLC from $150,000 to $200,000. The additional $50,000 was used to pay placement agent fees of $39,750 and Cantone Research Inc’s legal fees of $4,000. The remaining proceeds (approx $6,000) were remitted to the Company and used toward the repayment of the $10,000 in non-extending Series A Debentures. | |||||||
At December 31, 2013, the following are the maturities of long-term debt for each of the next five years: | ||||||||
2014 | $ | 1,226,000 | ||||||
2015 | 0 | |||||||
2016 | 0 | |||||||
2017 | 0 | |||||||
2018 | 0 | |||||||
$ | 1,226,000 | |||||||
FIRST NIAGARA: MORTGAGE CONSOLIDATION LOAN | ||||||||
On February 23, 2011, the Company amended and extended its Mortgage Consolidation Loan (the “Mortgage Consolidation Loan”) with First Niagara Bank (“First Niagara”). The amended Mortgage Consolidation Loan continues to be secured by the Company’s facility in Kinderhook, New York as well as various pieces of machinery and equipment. All other terms of the Mortgage Consolidation Loan remained unchanged, including compliance with a covenant (measured monthly) to maintain a certain level of liquidity (defined as any combination of cash, marketable securities or borrowing availability under one or more credit facilities other than the Mortgage Consolidation Loan). | ||||||||
The amended Mortgage Consolidation Loan had a maturity date of March 1, 2013, and had a 6-year (72 month) amortization. The principal amount of the amended Mortgage Consolidation Loan was $815,000 with a fixed interest rate of 8.25%. The monthly payment of principal and interest was $14,000 and payments commenced on March 1, 2011. The Company was required to make a $15,000 principal payment at the time of closing of the amended Mortgage Consolidation Loan. The Company also incurred approximately $2,000 in costs associated with this amendment, which were legal costs incurred by First Niagara and passed on to the Company. The Company amortized less than $1,000 of this expense in Fiscal 2013 and in Fiscal 2012. | ||||||||
On March 8, 2013, the Company entered into a Second Amendment to Loan Agreement (the “Second Mortgage Consolidation Loan Amendment”) with First Niagara. Under the Second Mortgage Consolidation Loan Amendment, the Mortgage Consolidation Loan was recast into a 4-year fully amortizing note with a one-year term through March 1, 2014 (See Note L – Subsequent Events). The interest rate was increased from 8.25% to 9.25% and the monthly payment was reduced to $14,115 from $14,437. The Company was required to make a principal reduction payment of $25,000 at the time of closing. All other terms of the Mortgage Consolidation Loan remained unchanged. | ||||||||
The balance on the Mortgage Consolidation Loan was $452,000 at the end of Fiscal 2013 and $608,000 at the end of Fiscal 2012. We recognized $48,000 and $56,000 in interest expense in Fiscal 2013 and Fiscal 2012, respectively. | ||||||||
RICOH | ||||||||
In May 2007, the Company purchased a copier through an equipment lease with RICOH in the amount of $17,000. The term of the lease was five years with an interest rate of 14.11%. In April 2012, the Company notified RICOH that it was opting to purchase the copier for $1.00 as provided in the Company’s lease. The amount outstanding on this lease was $0 at December 31 2013 and at December 31, 2012. | ||||||||
MARLIN | ||||||||
In October 2010, the Company purchased a copier through an equipment lease with Marlin Leasing in the amount of $4,000. The term of the lease was three years with an interest rate of 14.46%. The amount outstanding on this lease was $0 at December 31, 2013 and less than $1,000 at December 31, 2012. | ||||||||
DEBENTURE FINANCING | ||||||||
In August 2008, the Company completed an offering of Series A Debentures (“Series A Debentures”) and received gross proceeds of $750,000. The net proceeds of the offering of Series A Debentures were $631,000 after $54,000 of placement agent fees and expenses, legal and accounting fees of $63,000 and $2,000 of state filing fees. | ||||||||
The Series A Debentures accrued interest at a rate of 10% per annum (payable by the Company semi-annually). As placement agent, Cantone Research, Inc. (“Cantone”) received a placement agent fee of $52,500, or 7% of the gross principal amount of Series A Debentures sold. In addition, the Company issued Cantone a warrant to purchase 30,450 shares of the Company’s common stock at an exercise price of $0.37 per share and a warrant to purchase 44,550 shares of the Company’s common stock at an exercise price of $0.40 per share. | ||||||||
The Company incurred $131,000 in expenses related to the offering, including $12,000 in expense related to warrants issued to Cantone. The Company amortized $0 of this expense and $19,000 of this expense (of which a little under $2,000 was related to share based payment expense related to the Cantone warrants) in Fiscal 2013 and Fiscal 2012, respectively. | ||||||||
The unamortized balance was $0 at the end of Fiscal 2013 and Fiscal 2012, (as the Series A Debentures matured on August 1, 2012). | ||||||||
Series A Debenture Extension | ||||||||
The Series A Debentures matured on August 1, 2012. On July 25, 2012, the Company entered into a Placement Agent Agreement (the “Agent Agreement”) with Cantone. Under the terms of the Agent Agreement, Cantone acted as the Company’s exclusive placement agent in connection with an amendment of the Series A Debentures. Under the amendment, the term of Series A Debentures was extended to reflect a due date of August 1, 2013, and the interest rate during the extension period was increased from 10% to 15% per annum, due quarterly in arrears. | ||||||||
As compensation for their placement agent services, Cantone received a cash fee of 5% of the gross amount of existing Series A Debentures, or $37,500. Cantone also received 1% of the gross amount of Series A Debentures, or $7,500, as a non-accountable expense allowance and the Company reimbursed Cantone $5,000 in legal fees incurred in connection with the amendment of the Series A Debentures. These costs, totaling $50,000 were amortized over the term of the extension (12 months). The Company amortized $29,000 of this expense in Fiscal 2013 and $21,000 of expense in Fiscal 2012. | ||||||||
The warrants issued to Cantone (in connection with their services as placement agent in the original Series A Debenture financing) were also amended to reflect a purchase price of $0.17 per share and a new term of three (3) years. The Company incurred $12,000 in share based payment expense related to this amendment, which was fully expensed in Fiscal 2012. | ||||||||
On July 30, 2012, the Company entered into a Bridge Loan Agreement and Note (the “Bridge Loan”) with Cantone Asset Management, LLC (“CAM”). The Bridge Loan was in the amount of $150,000 and was used to pay $100,000 to those Holders of Series A Debentures that did not wish to amend/extend the Series A Debentures and $50,000 was used to pay placement agent fees and expenses indicated in the previous paragraph. The maturity date of the Bridge Loan was August 1, 2013 bearing simple interest in advance of 15%. In addition to the interest, on August 1, 2012, the Company issued CAM restricted stock of the Company equal to 10% of the gross amount of existing Series A Debentures, or $15,000 using a value of $0.17 per common share. On August 8, 2012, 88,235 restricted common shares were issued to CAM. | ||||||||
On July 31, 2012, the Company entered into an Agreement to the Series A Debenture (the “Series A Debenture Amendment”) with thirty-two of the thirty-seven holders of Series A Debentures (the “Debenture Holders”) (representing $645,000 of Series A Debentures). As previously indicated, the Series A Debenture Amendment extended the due date of the Series A Debentures to August 1, 2013 and increased the interest rate to 15% per annum, payable quarterly in arrears. All other terms of the Series A Debentures remained unchanged. Five of the Debenture Holders (representing $105,000 in Series A Debentures) did not wish to extend the Series A Debentures and the Company used proceeds of $100,000 from the Bridge Loan and $5,000 paid directly from the Company to pay principal amounts due to these non-extending Debenture Holders. | ||||||||
2013 Series A Debenture Extension | ||||||||
On October 7, 2013, the Company entered into a new Placement Agent Agreement (“2013 Agent Agreement”) with Cantone related to the further extension of the Series A Debentures, as amended, due August 1, 2013. Under the terms of the 2013 Agent Agreement, Cantone acted as the Company’s exclusive placement agent in connection with an amendment of the Series A Debentures. Under the amendment, the term of Series A Debentures was extended to reflect a due date of either February 1, 2014 or August 1, 2014, at the election of the Series A Debenture Holder. The interest rate during the extension period remains 15% per annum, due quarterly in arrears. All other terms of the Series A Debentures remain the same. | ||||||||
As compensation for their placement agent services, Cantone received 1) a cash fee of 5% ($39,750) of the gross amount ($795,000) of existing Series A Debentures and the CAM note combined, 2) a 3-year warrant to purchase 75,000 common shares at an exercise price of $0.14 (the average closing sale price of the Company’s common shares for the 5 days business days ending October 7, 2013), and 3) a non-accountable expense allowance paid with 115,000 restricted shares of ABMC common stock (in lieu of cash). The Company also paid $4,000 in legal fees incurred by Cantone. These costs are being amortized over the term of the 12-month extension. The Company amortized $25,000 in costs in Fiscal 2013 and $0 in Fiscal 2012 (as the Company did not enter into the extension until October 2013). The fair value of the Cantone warrant was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 2.65; expected life of 10 years; and stock price volatility of 73%. The value of the Cantone warrant was $10,000 and the Company recognized 100% of this expense on the date of the grant, or $10,000 in Fiscal 2013. | ||||||||
On October 7, 2013, the Company entered into a new Bridge Loan Agreement and Note (the “2013 Bridge Loan”) with CAM. The 2013 Bridge Loan is in the amount of $200,000 and was used to pay off the existing Bridge Loan with Cam ($150,000) and the remaining $50,000 was used to pay placement agent fees and expenses as indicated in the preceding paragraph. Net proceeds of $6,250 were remitted to the Company. The 15% interest on the existing Bridge Loan of $150,000 was paid with 225,000 restricted shares of ABMC common stock. | ||||||||
The maturity date of the 2013 Bridge Loan is August 1, 2014 and it bears simple interest in advance of 15% to be paid in the form of 300,000 shares of restricted shares of ABMC common stock. In addition to the interest, as inducement to enter into the 2013 Bridge Loan, the Company issued 153,486 restricted shares of ABMC common stock, and the Company issued CAM a 3-year warrant to purchase 250,000 common shares at an exercise price of $0.14 (the average closing sale price of the Company’s common shares for the 5 days business days ending October 7, 2013). The warrants were 100% exercisable on the date of the grant. The fair value of the CAM warrant was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 2.65; expected life of 10 years; and stock price volatility of 73%. The value of the warrant was $35,000 and the Company recognized 100% of this expense on the date of the grant, or $35,000 in Fiscal 2013. | ||||||||
On October 7, 2013, the Company entered into an Agreement to the Series A Debenture (the “2013 Series A Debenture Amendment”) with 30 of the 32 holders of Series A Debentures (the “Debenture Holders”) (representing $634,500 of Series A Debentures). One of the Debenture Holders (representing $10,500 in Series A Debentures) did not wish to extend and the Company used the net proceeds and cash on hand to pay the principal amount due to this Holder. One of the Debenture Holders transferred their investment to another existing Debenture Holder. As previously indicated, the extension period of either 6 or 12 months was at the election of the Debenture Holder. 27 of the 30 Debenture Holders (representing $543,500 of Series A Debentures) elected to extend for a period of 12 months. The other 3 (representing $91,000 in Series A Debentures) elected to extend for a period of 6 months. The 27 holders that elected to extend for a 12-month period were each issued a warrant to purchase 1 shares of common stock for each $1.00 that was extended. The Company issued 2 year warrants to purchase 543,500 shares of ABMC common stock at an exercise price of $0.14 (the average closing sale price of our common shares for the 5 days business days ending October 7, 2013). The fair value of the Debenture Holder warrants was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 2.65; expected life of 10 years; and stock price volatility of 73%. The value of the warrants was $76,000 and we are amortizing this cost over the term of the Series A Debenture extension, or 12 months. The Company recognized $32,000 in expense in Fiscal 2013. As of December 31, 2013, there was $44,000 in unrecognized debt issuance expense with 7 months remaining. | ||||||||
The Company recognized $122,000 in interest expense in Fiscal 2013 and $93,000 in Fiscal 2012. The Company had $27,000 in accrued interest expense at the end of Fiscal 2013, and $26,000 in accrued interest expense at the end of Fiscal 2012. In Fiscal 2013, the Company recorded a debt discount in the amount of $60,000 related to securities issued in connection with the Series A Debentures. | ||||||||
LINES_OF_CREDIT
LINES OF CREDIT | 12 Months Ended |
Dec. 31, 2013 | |
Debt Disclosure [Abstract] | ' |
Debt Disclosure [Text Block] | ' |
NOTE F – LINES OF CREDIT | |
Line of Credit with Imperium Commercial Finance, LLC (“Imperium”) | |
On January 16, 2013 (the “Imperium Closing Date”), the Company entered into a 3-year Loan and Security Agreement (“LSA”) with Imperium, a new Senior Lender, to refinance its Line of Credit with Medallion Financial Corp (“Medallion”), see below for information on the Medallion Line of Credit. | |
Under the LSA, Imperium agreed to provide the Company with up to a maximum amount of $1,500,000 (“Maximum Funding Amount”) under a revolving secured loan facility (the “Imperium Line of Credit”), which is secured by a first security interest in all of the Company’s receivables, inventory, and intellectual property rights along with a second security interest in the Company’s machinery and equipment (together the “Collateral”). The Maximum Funding Amount is subject to a discretionary borrowing base comprised of: 85% of eligible accounts receivables (excluding, without limitation, receivables remaining unpaid for more than 90 days from invoice date or 60 days from due date, contra receivables, and affiliated receivables), up to the lesser of 60% of eligible finished goods inventory at cost or 75% of appraised net orderly liquidation value of inventory, and a receivable dilution rate of less than 5% (the “Borrowing Base”). | |
In addition to the Imperium Line of Credit, the Imperium facility included a discretionary Supplemental Advance of up to $500,000 (the “Imperium Supplemental Advance”). Supplemental advances, once repaid, could not be re-borrowed, and advances were secured with the same Collateral as the Imperium Line of Credit. | |
The Imperium Line of Credit is used for working capital and general corporate purposes, and the Imperium Supplemental Advance was used for costs associated with obtaining marketing clearance of our oral fluid products and costs associated with other new market opportunities. | |
On the Imperium Closing Date, the Company paid a closing fee of $10,000 to Imperium, and granted Imperium a 7-year warrant to purchase 2,000,000 common shares of the Company at an exercise price of $0.18 (the “Imperium Warrants”). The Company also paid an early termination fee of $25,000 to Medallion on the Imperium Closing Date, a finder’s fee of 3% of the gross proceeds from the Imperium financing, or $60,000, and a 5-year warrant (the “Monarch Warrant”) to purchase 60,000 common shares of the Company at an exercise price of $0.18 to Monarch Capital Group, LLC. | |
The Company also pays Imperium an Unused Line Fee in an amount equal to 2% (a) from and after the Imperium Closing Date through and including March 31, 2013, the Maximum Revolving Amount less the aggregate amounts outstanding to Imperium and (b) at all time from and after April 1, 2013, the Maximum Amount of $2,000,000 less the aggregate amounts outstanding to Imperium. The Unused Line Fee for each month (except for the month in which the termination occurs) is payable on the first day of each calendar month following the Imperium Closing Date; the final monthly installment of the Unused Line Fee is payable on the termination date. The Company also pays to Imperium a Collateral monitoring fee of $2,500 on the first day of each month during the term of the LSA. | |
A success fee of $175,000 (“Success Fee”) is due and payable if Imperium terminates due to an event of default, or if the Company terminates and pre-pays all amounts due to Imperium prior to the stated expiration date of January 16, 2016, however, the Success Fee is not due and payable if Imperium has exercised all its rights under the Imperium Warrant and sells all of the common shares underlying the Imperium Warrant on or before January 16, 2016 and if on the date that Imperium completes such sale(s), the price per share of the Company’s common shares is at least $0.70 per common share. | |
Under the LSA, interest on the Imperium Line of Credit and the Imperium Supplemental Advance is in cash at a rate equal to eight percent (8%) per annum and (ii) in kind (i.e., “PIK” interest) at a rate equal to two percent (2%) per annum (collectively, the “Interest Rate”), all of which “PIK” interest shall be added to and constitute a part of the aggregate principal amount of outstanding Line of Credit borrowing or aggregate principal amount of outstanding Supplemental Advances, as applicable, as and when such “PIK” interest becomes due and payable hereunder. Interest is payable on the Line of Credit and Supplemental Advance in arrears for the preceding calendar month on the first day of each calendar month. | |
So long as any obligations are due to Imperium under the LSA, the Company must maintain Net Borrowing Availability of not less than $100,000 (Net Borrowing Availability is defined as borrowing availability less the amounts due under the Imperium Line of Credit). There are also certain minimum EBITDA (Earnings Before Interest, Taxes Depreciation and Amortization) requirements. More specifically, the Company must have EBITDA of not less than (a) $25,000 for the Fiscal Quarter ended on or about March 31, 2013, (b) $100,000 for the Fiscal Quarter ended on or about June 30, 2013, (c) $200,000 for the Fiscal Quarter ending on or about September 30, 2013, and (d) $300,000 for the Fiscal Quarter ending on or about December 31, 2013 and for each of the Fiscal Quarters thereafter. | |
The Company incurred $435,000 in costs related to the Imperium Line of Credit, which included the costs noted previously as well as $39,000 to Imperium for their legal fees, $2,000 for the Company’s legal fees and $9,000 in capitalized deferred financing costs and $290,000 as debt discount associated with the warrants issues to Imperium and Monarch. With the exception of the early termination fee of $25,000 paid to Medallion (which was fully recognized in the three months ended March 31, 2013), these costs are being amortized over the term of the facility (3 years). The Company recognized $257,000 of these costs in Fiscal 2013, of which $193,000 was debt discount recorded against the line of credit, and $0 in costs in Fiscal 2012 (as the Company didn’t enter into the LSA with Imperium until January 2013). The Company incurred $122,000 in interest expense in Fiscal 2013, and $0 in interest expense in Fiscal 2012 (as the Company did not enter into the LSA with Imperium until January 2013). | |
In an event of default, which includes but is not limited to, failure of the Company to make any payment when due, and non-compliance with the Net Borrowing Availability and minimum EBITDA requirements, the interest rate can be increased by 4% for as long as the event of default occurs. Imperium’s other remedies include, but are not limited to, termination or suspension of Imperium’s obligation to make further advances to the Company, declaration of all amounts owed to Imperium due and payable. The Company did not comply with the minimum EBITDA requirement for the quarter ending March 31, 2013, however, upon conferences with Imperium, on May 20, 2013, Imperium waived the EBITDA requirement for the quarter ended March 31, 2013. Imperium was paid $10,0000 for costs related to account review. The Company also did not comply with the EBITDA requirement for the quarter ended June 30, 2013 or September 30, 2013, and as of the date of this report, the Company is not in compliance with the EDBITDA requirement for the quarter ended December 31, 2013 (to be measured upon the filing of this Form 10-K). EBITDA non-compliance constitutes an event of default under the Imperium Line of Credit. The increase in interest rate, given the Company’s current advances under the Imperium Line of Credit would not be material, however, if Imperium were to suspend or terminate further advances, or declare all amounts due and payable, this would have a material adverse effect on the Company’s business and negatively impact the Company’s ability to continue operations. | |
In late July 2013, Imperium notified the Company that it was reducing the Maximum Funding Amount on the Imperium Line of Credit from $1,500,000 to $1,100,000 (however, the Company must continue to maintain minimum Net Borrowing Availability of $100,000 so in essence the maximum amount available under the Imperium Line of Credit is $1,000,000) and that no further advances would be made under the Imperium Supplemental Advance. We are currently in discussions with Imperium related to the EBITDA non-compliance and any further actions they may take. | |
The balance on the Imperium Line of Credit was $980,000, and the balance on the supplemental advance was $200,000, for a total loan balance of $1,180,000 at December 31, 2013. There was a debt discount recorded in the amount of $193,000 in Fiscal 2013 related to securities issued in connection with the Imperium Line of Credit. There was $0 outstanding to Imperium at December 31, 2012, as the Company did not enter into the LSA with Imperium until January 2013. As of December 31, 2013, additional loan availability on the line of credit was $20,000 and since Imperium suspended further advances under the Supplemental Advance, there was $0 in availability under the Supplemental Advance, for a total Loan Availability of $20,000 at December 31, 2013. | |
Loan and Security Agreement with Medallion | |
On April 20, 2012 (the “Medallion Closing Date”), the Company entered into a Loan and Security Agreement (the “Loan Agreement”) with Medallion to refinance its Line of Credit with Rosenthal and Rosenthal, Inc (“Rosenthal”; see below for information on the Rosenthal Line of Credit). | |
Under the Loan Agreement, Medallion provided the Company with up to $1,000,000 under a revolving secured line of credit (the “Medallion Line of Credit”), which was secured by a first security interest in all of the Company’s receivables, inventory, and intellectual property rights along with a second security interest in the Company’s machinery and equipment. The maximum amount available under the Medallion Line of Credit was subject to an Advance Rate that consisted of: 85% of eligible accounts receivable and up to 30% of eligible inventory (not to exceed $150,000). | |
From the loan availability on the Medallion Closing Date, the Company drew approximately $566,000 to pay off our Line of Credit with Rosenthal. The Company was charged a facility fee of 1% of the balance of the Medallion Line of Credit on the Medallion Closing Date and the same facility fee of 1% would be charged on each anniversary of the Medallion Closing Date. Under the Loan Agreement, interest on outstanding borrowings was payable monthly and was charged at an annual rate equal to 4% above the Wall Street Journal Prime rate as published from time to time. The Company was subject to two audits per year by Medallion (provided we were not in default) at a rate of $950.00 per person per day. Prior to the Medallion Closing Date, the Company also paid a non-refundable fee in the amount of $10,000 to Medallion for field exam and due diligence costs. | |
The Company incurred $20,000 in costs related to the Medallion Line of Credit. These costs were fully expensed in Fiscal 2012 so, although the Medallion Line of Credit was in place for a few weeks in January 2013, there was $0 in cost expensed in Fiscal 2013. The Company incurred $8,000 in interest expense in Fiscal 2013 (as the Medallion Line of Credit was only in place for a few weeks in January 2013) and $42,000 in interest expense in Fiscal 2012. | |
The amount outstanding on the Medallion Line of Credit at the end of Fiscal 2013 was $0 since, on January 16, 2013, all indebtedness due to Medallion was paid in full and Medallion’s security interest in the Company’s assets were terminated. The amount outstanding on the Medallion Line of Credit at the end of Fiscal 2012 was $321,000. | |
Line of Credit with Rosenthal and Rosenthal, Inc. (“Rosenthal”) | |
In July 2009, the Company entered into a Financing Agreement (the “Financing Agreement”) with Rosenthal. Under the Financing Agreement, Rosenthal provided the Company with up to $1,500,000 under a revolving secured line of credit (“Rosenthal Line of Credit”). The Rosenthal Line of Credit was collateralized by a first security interest in all of the Company’s accounts receivables, inventory, and intellectual property, and a second security interest in the Company’s machinery and equipment, leases, leasehold improvements, furniture and fixtures. The maximum availability of $1,500,000 was subject to an availability formula based on certain percentages of accounts receivable and inventory, and elements of the availability formula were subject to periodic review and revision by Rosenthal. Under the Financing Agreement, the Company paid Rosenthal an administrative fee of $1,500 per month and an annual fee of $15,000. Under the Financing Agreement, interest was payable monthly, and was charged at variable rates (based on the Prime Rate), with minimum monthly interest of $4,000. | |
On February 28, 2012, the Company gave Rosenthal written notice of non-renewal as provided under the Financing Agreement, and in April 2012, the Company drew approximately $566,000 from our Medallion Line of Credit to pay off the Rosenthal Line of Credit. | |
The Company incurred $41,000 in costs related to the Rosenthal Line of Credit. These costs were amortized over the three-year term of the Rosenthal Line of Credit. The Company amortized $0 of these costs in Fiscal 2013 (given the Rosenthal Line of Credit was terminated on May 30, 2012), and $7,000 of these costs in Fiscal 2012. | |
The Company incurred $0 in interest expense in Fiscal 2013 (again, given the May 2013 termination date), and $19,000 in Fiscal 2012. There was $0 outstanding on the Rosenthal Line of Credit at the end of Fiscal 2013 and Fiscal 2012. | |
INCOME_TAXES
INCOME TAXES | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Income Tax Disclosure [Abstract] | ' | |||||||
Income Tax Disclosure [Text Block] | ' | |||||||
NOTE G – INCOME TAXES | ||||||||
A reconciliation of the U.S. Federal statutory income tax rate to the effective income tax rate is as follows: | ||||||||
Year Ended | Year Ended | |||||||
December 31, 2013 | December 31, 2012 | |||||||
Tax expense at federal statutory rate | 34 | % | 34 | % | ||||
State tax expense, net of federal tax effect | 5 | % | 5 | % | ||||
Permanent timing differences | -10 | % | -4 | % | ||||
Deferred income tax asset valuation allowance | -29 | % | -35 | % | ||||
Effective income tax rate | 0 | % | 0 | % | ||||
Significant components of the Company’s deferred income tax assets are as follows: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
Inventory | $ | 15,000 | $ | 18,000 | ||||
Inventory allowance | 156,000 | 102,000 | ||||||
Allowance for doubtful accounts | 23,000 | 23,000 | ||||||
Accrued compensation | 27,000 | 27,000 | ||||||
Net operating loss carry forward expired | 0 | -197,000 | ||||||
Net operating loss carry-forward | 5,026,000 | 5,013,000 | ||||||
Total gross deferred income tax assets | 5,247,000 | 4,986,000 | ||||||
Less deferred income tax assets valuation allowance | -5,247,000 | -4,986,000 | ||||||
Net deferred income tax assets | $ | 0 | $ | 0 | ||||
The valuation allowance for deferred income tax assets as of December 31, 2013 and December 31, 2012 was $5,247,000 and $4,986,000, respectively. The net change in the deferred income tax assets valuation allowance was $261,000 for Fiscal 2013. The net change in the deferred income tax assets valuation allowance was an increase of $213,000 for Fiscal 2012. | ||||||||
As of December 31, 2013, the prior three years remain open for examination by the federal or state regulatory agencies for purposes of an audit for tax purposes. | ||||||||
At December 31, 2013, the Company had Federal and New York State net operating loss carry-forwards for income tax purposes of approximately $12,888,000. The Company’s net operating loss carry-forwards began to expire in 2011 and continue to expire through 2033. In assessing the realizability of deferred income tax assets, management considers whether or not it is more likely than not that some portion or all deferred income tax assets will be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the projected future taxable income and tax planning strategies in making this assessment. | ||||||||
The Company’s ability to utilize the operating loss carry-forwards may be subject to an annual limitation in future periods pursuant to Section 382 of the Internal Revenue Code of 1986, as amended, if future changes in ownership occur. | ||||||||
The Company recognizes potential interest and penalties related to income tax positions as a component of the provision for income taxes on operations. The Company does not anticipate that total unrecognized tax benefits will materially change in the next twelve months. | ||||||||
OTHER_INCOME_EXPENSE
OTHER INCOME / EXPENSE | 12 Months Ended |
Dec. 31, 2013 | |
Other Income and Expenses [Abstract] | ' |
Other Income and Other Expense Disclosure [Text Block] | ' |
NOTE H – OTHER INCOME / EXPENSE | |
Other income in Fiscal 2013 consisted primarily of proceeds from a key man insurance policy (received in the latter part of Fiscal 2013) maintained on our former CEO/CFO Stan Cipkowski. Other income during Fiscal 2012 consisted of grant income of $10,000 offset by $1,000 loss on sale of assets. The grant was originally received from the Columbia Economic Development Corporation and totaled $100,000. The grant was convertible to a loan based upon a percentage of the grant declining from 90% of the grant amount in 2003 to 0% in 2012. The grant was convertible to a loan only if the employment levels in the Kinderhook facility dropped below 45 employees at any time during the year. The employment level in the Kinderhook facility was 47 in Fiscal 2012; the last milestone year. | |
STOCKHOLDERS_EQUITY
STOCKHOLDERS' EQUITY | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Stockholders Equity Note [Abstract] | ' | ||||||||||||||||
Stockholders Equity Note Disclosure [Text Block] | ' | ||||||||||||||||
NOTE I – STOCKHOLDERS’ EQUITY | |||||||||||||||||
[1] Stock option plans: The Company currently has three non-statutory stock option plans, the Fiscal 2000 Non-statutory Stock Option Plan (the “2000 Plan”), the Fiscal 2001 Non-statutory Stock Option Plan (the “2001 Plan”) and the 2013 Equity Compensation Plan (the “2013 Plan”). All three plans have been adopted by our Board of Directors and approved by our shareholders. The 2000 Plan for the granting of options to purchase up to 1,000,000 common shares, and the 2001 Plan and the 2013 Plan each provide for the granting of options to purchase up to 4,000,000 common shares. Both the 2000 Plan and the 2001 Plan have options issued. Only the 2001 Plan and the 2013 Plan have options available for future issuance. As of December 31, 2013, there were 9,000 options issued and outstanding under the 2000 Plan and 3,307,000 options issued and outstanding under the 2001 Plan, for a total of 3,316,000 options issued and outstanding as of December 31, 2013 (there are no options issued under the 2013 Plan). Of the total options issued and outstanding, 2,747,000 are fully vested as of December 31, 2013. As of December 31, 2013, there were 409,000 options available for issuance under the 2001 Plan and 4,000,000 options available for issuance under the 2013 Plan. Any common shares issued as a result of the exercise of stock options would be new common shares issued from our authorized issued shares. | |||||||||||||||||
[2] Stock options: During Fiscal 2013 and Fiscal 2012, the Company issued options to purchase 902,000 and 750,000 shares respectively, of common stock under the 2001 Plan: | |||||||||||||||||
June 2013 Stock Options | |||||||||||||||||
On June 20, 2013, the Company issued options to purchase 25,000 shares of the Company’s common stock under our Fiscal 2001 Stock Option Plan (“2001 Option Plan”) to a member of our Science Advisory Board (“SAB”). The SAB was recently put back into place after being inactive for a number of years. New members were added to the SAB in 2013 in our efforts to diversify our business and explore new technologies. The stock option has an exercise price of $0.14, the closing price of the Company’s common shares on June 20, 2013, and it vests over 24 months as follows: 12,500 common shares on June 20, 2014, and 12,500 common shares on June 20, 2015. The fair value of these options is $4,000 and was estimated using the Black-Scholes pricing model using the following weighted average assumptions: dividend yield of 0%; risk-free interest rate of 2.41; expected life of 10 years; and stock price volatility of 74%. The Company will amortize this share based payment expense over the vesting period (24 months). The Company recognized $1,000 in share based payment expense in Fiscal 2013, and $0 in expense in Fiscal 2012 (as these options were not issued until June 2013). As of December 31, 2013, there was $3,000 in unrecognized share based payment expense with 17 months remaining. | |||||||||||||||||
On June 25, 2013, the Company issued options to purchase 200,000 shares of the Company’s common stock under our 2001 Option Plan to our (then) executive vice president and chief compliance officer, Melissa Waterhouse (“Waterhouse”); Waterhouse was subsequently appointed as interim CEO/CFO in October 2013. The Waterhouse stock option has an exercise price of $0.14, the closing price of the Company’s common shares on June 25, 2013 and it vests over 36 months as follows: 66,000 common shares on June 25, 2014; 66,000 common shares on June 25, 2015 and 68,000 common shares on June 20, 2016. The fair value of these options is $28,000 and was estimated using the Black-Scholes pricing model using the following weighted average assumptions: dividend yield of 0%; risk-free interest rate of 2.60; expected life of 10 years; and stock price volatility of 74%. The Company will amortize this share based payment expense over the vesting period (36 months). The Company amortized $5,000 of this share based payment expense in Fiscal 2013 and $0 in share based payment expense in Fiscal 2012 (as these options were not issued until June 2013). As of December 31, 2013, there was $23,000 in unrecognized share based payment expense with 29 months remaining. | |||||||||||||||||
April 2013 Stock Options | |||||||||||||||||
On April 15, 2013, the Company issued options to purchase 25,000 shares of the Company’s common stock under its 2001 Option Plan to another member of our SAB. The stock option has an exercise price of $0.16, the closing price of the Company’s common shares on April 15, 2013, and it vests over 24 months as follows: 12,500 common shares on April 15, 2014 and 12,500 common shares on April 15, 2015. The fair value of these options is $4,000 and was estimated using the Black-Scholes pricing model using the following weighted average assumptions: dividend yield of 0%; risk-free interest rate of 1.72; expected life of 10 years; and stock price volatility of 76%. The Company will amortize this share based payment expense over the vesting period (24 months). The Company recognized $2,000 in share based payment expense in Fiscal 2013, and $0 in share based payment expense in Fiscal 2012 (as these options were not issued until April 2013). As of December 31, 2013, there was $2,000 in unrecognized share based payment expense with 15 months remaining. | |||||||||||||||||
On April 26, 2013, the Company issued options to purchase 50,000 shares of the Company’s common stock under its 2001 Option Plan to a consultant. The stock option has an exercise price of $0.18, the closing price of the Company’s common shares on April 26, 2013, and it vests over 24 months as follows: 25,000 common shares on April 26, 2014 and 25,000 common shares on April 26, 2015. The fair value of these options is $9,000 and was estimated using the Black-Scholes pricing model using the following weighted average assumptions: dividend yield of 0%; risk-free interest rate of 1.70; expected life of 10 years; and stock price volatility of 76%. The Company will amortize this share based payment expense over the vesting period (24 months). The Company recognized $3,000 of this share based payment expense in Fiscal 2013 and $0 in share based payment expense in Fiscal 2012 (as these options were not issued until April 2013). As of December 31, 2013, there was $6,000 in unrecognized share based payment expense with 15 months remaining. | |||||||||||||||||
February 2013 Employee/Consultant Stock Options | |||||||||||||||||
On February 21, 2013, the Company issued options to purchase 102,000 shares of common stock under its 2001 Option Plan to 1 executive officer (Waterhouse), 13 non-executive employees of the Company, and 1 consultant at an exercise price of $0.26, the closing price of the Company’s common shares on February 21, 2013 (the “February 2013 Stock Options”). The February 2013 Stock Options vest 100% on the 12 month anniversary of the date of the grant, or on February 21, 2014. The fair value of the February 2013 Stock Options is $27,000 and was estimated using the Black-Scholes pricing model using the following weighted average assumptions: dividend yield of 0%; risk-free interest rate of 1.99; expected life of 10 years; and stock price volatility of 82%. The Company will amortize this share based payment expense over the vesting period of 12 months. The Company recognized $24,000 of this share based payment expense in Fiscal 2013, and $0 in share based payment expense in Fiscal 2012 (as these stock options were not issued until February 2013). As of December 31, 2013, there was $3,000 in unrecognized share based payment expense with 1 month remaining. | |||||||||||||||||
Imperium Financing Stock Options | |||||||||||||||||
On January 16, 2013, as compensation for his execution of a Personal Guarantee required under the Imperium LSA, the Company’s (then) Chief Executive Officer, Stan Cipkowski (“Cipkowski”) was awarded an option grant representing 500,000 common shares of the Company under our 2001 Option Plan, at an exercise price of $0.15, the closing price of our common shares on January 16, 2013 (the “Cipkowski Imperium Stock Option”). The Cipkowski Imperium Stock Option vests over 36 months in equal installments as follows: 165,000 common shares on January 16, 2014, 165,000 common shares on January 16, 2015 and 170,000 common shares on January 16, 2016. The fair value of the Cipkowski Imperium Stock Option is $73,000 and was estimated using the Black-Scholes pricing model using the following weighted average assumptions: dividend yield of 0%; risk-free interest rate of 1.84; expected life of 10 years; and stock price volatility of 82%. This share based payment expense was originally being amortized over the vesting period of 36 months. Given this, through the nine months ended September 30, 2013, the Company recognized $18,000 in share based payment expense, and $0 in share based payment expense in Fiscal 2012 (as the Cipkowski Imperium Stock Option was not granted until January 2013). On November 1, 2013, we were notified of Mr. Cipkowski’s death. Under the terms of this Cipkowski stock option grant, any unvested portion of the stock option became immediately exercisable upon Mr. Cipkowski’s death. As a result, we are no longer amortizing the Cipkowski Imperium Stock Option; rather we recognized the remaining $54,000 in expense in the three months ended December 31, 2013, for a total of $73,000 in share based payment expense in Fiscal 2013 and $0 in share based payment expense in Fiscal 2012 (since the Cipkowski Imperium Stock Option was not granted until January 2013). As of December 31, 2013, there was $0 in unrecognized share based payment expense related to the Cipkowski Imperium Stock Option with 0 months remaining. | |||||||||||||||||
September 2012 Employee Stock Options | |||||||||||||||||
On September 20, 2012, the Company issued 2 stock option grants to purchase 50,000 shares each (for a total of 100,000) of the Company’s common stock to 2 non-executive employees at an exercise price of $0.18 (the closing price of the Company’s common shares on the date of the grant) (“September 2012 Stock Options”). The September 2012 Stock Options vest over 36 months in installments as follows: 33,000 common shares on September 20, 2013, 33,000 common shares on September 20, 2014 and 34,000 common shares on September 20, 2015. The fair value of the September 2012 Stock Options is $18,000 and was estimated using the Black-Scholes pricing model using the following weighted average assumptions: dividend yield of 0%; risk-free interest rate of 1.80; expected life of 10 years; and stock price volatility of 85%. The Company will amortize this share based payment expense over the vesting period of 36 months. The Company recognized $6,000 of this share based payment expense in Fiscal 2013, and $2,000 in share based payment expense in Fiscal 2012. As of December 31, 2013, there was $10,000 in unrecognized share based payment expense with 20 months remaining. | |||||||||||||||||
Medallion Line of Credit Stock Options | |||||||||||||||||
As a condition to the Medallion Line of Credit, Cipkowski and the Company’s (then) controller J. Duncan Urquhart (“Urquhart”) were each required to execute Validity Guarantees (the “Validity Guarantees”). Under the Validity Guarantees, Cipkowski and Urquhart provided representations and warranties with respect to the validity of the Company’s receivables as well as guaranteeing the accuracy of the Company’s reporting to Medallion related to the Company’s receivables. As compensation for their execution of the Validity Guarantees, on April 20, 2012, Cipkowski and Urquhart were each awarded an option grant representing 250,000 common shares of the Company under our 2001 Option Plan, at an exercise price of $0.18, the closing price of our common shares on the date of the grant. The option grants originally vested over 36 months as follows: 82,500 common shares on April 20, 2013, 82,500 common shares on April 20, 2014 and 85,000 common shares on April 20, 2015. The fair value of the Cipkowski and Urquhart stock option grants was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 1.99; expected life of 10 years; and stock price volatility of 88%. The value of each of these 2 stock option grants was $45,000 (for a total of $90,000). | |||||||||||||||||
This share based payment expense was to be recognized over the vesting period of 36 months. However, on August 6, 2013, Urquhart was terminated from employment and 167,500 stock options (the unvested portion of his stock option grant) was cancelled and returned to the Fiscal 2001 Stock Option Plan. The share based payment expense of $13,000 recorded through August 2013 for these unvested options was reversed and no further expense incurred. 82,500 stock options (the vested portion) remained exercisable until November 6, 2013 under the terms of Urquhart’s stock option agreement, however the options were never exercised and on November 7, 2013, the 82,500 remaining Urquhart options were cancelled. The Company amortized $10,000 in share based payment expense in Fiscal 2013, however this was offset by the reversal of $13,000 indicated above, and $11,000 in share based payment expense in Fiscal 2012. As of December 31, 2013, there was $0 in unrecognized share based payment expense with 0 months remaining related to the Urquhart grant. | |||||||||||||||||
Also, on November 1, 2013, the Company was notified of Mr. Cipkowski’s death. Under the terms of this Cipkowski stock option grant, any unvested portion of the stock option became immediately exercisable upon Mr. Cipkowski’s death. As a result, the Company is no longer amortizing the Cipkowski Medallion Stock Option; rather the Company recognized the remaining $23,000 in expense in the three months ended December 31, 2013, for a total of $34,000 in share based payment expense in Fiscal 2013 and $11,000 in share based payment expense in Fiscal 2012. As of December 31, 2013, there was $0 in unrecognized share based payment expense related to the Cipkowski Medallion Stock Option with 0 months remaining. | |||||||||||||||||
As another condition to the financing, Edmund Jaskiewicz, the Company’s President and Chairman of the Board (“Jaskiewicz”) was required to execute another Subordination Agreement (“Subordination Agreement”) related to the Jaskiewicz Debt (the $124,000 currently owed to Jaskiewicz by the Company). Under the Subordination Agreement, the Jaskiewicz Debt was not payable, was junior in right to the Medallion Line of Credit and no payment could be accepted or retained by Jaskiewicz for the Jaskiewicz Debt unless and until the Company paid and satisfied in full any obligations to Medallion. As compensation for his execution of the Subordination Agreement, on April 20, 2012, Jaskiewicz was awarded an option grant representing 150,000 common shares of the Company under the Company’s Fiscal 2001 stock option plan, at an exercise price of $0.18, the closing price of the Company’s common shares on the date of the grant. The option grant vests over 36 months as follows: 49,500 common shares on April 20, 2013, 49,500 common shares on April 20, 2014 and 51,000 common shares on April 20, 2015. The fair value of the Jaskiewicz stock option grant was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 1.99; expected life of 10 years; and stock price volatility of 88%. The value of the stock option grant totaled $27,000 and the Company will recognize this share-based payment expense over the vesting period of 36 months. The Company recognized $9,000 in share based payment expense in Fiscal 2013 and $7,000 in share based payment expense in Fiscal 2012. As of December 31 2013, there was $11,000 in unrecognized share based payment expense with 15 months remaining. | |||||||||||||||||
In addition to the Stock Options issued in Fiscal 2013 and Fiscal 2012, the following stock options/warrants were issued prior to Fiscal 2012 but have a portion of their expense recognized in Fiscal 2012: | |||||||||||||||||
Rosenthal Line of Credit Validity Guarantee Stock Options | |||||||||||||||||
As a condition to the Rosenthal Line of Credit closing, Cipkowski was required to execute a Validity Guarantee (the “Validity Guarantee”). Under the Validity Guarantee, Cipkowski provided representations and warranties with respect to the validity of the Company’s receivables and guarantees the accuracy of the Company’s reporting to Rosenthal related to the Company’s receivables and inventory. The Validity Guarantee placed Cipkowski’s personal assets at risk in the event of a breach of such representations, warranties and guarantees. As part of the compensation for his execution of the Validity Guarantee, on July 1, 2009, Cipkowski was awarded an option grant representing 500,000 common shares of the Company under the Company’s 2001 Plan, at an exercise price of $0.20, the closing price of the Company’s common shares on the date of the grant. The option grant vested over three years in equal installments. | |||||||||||||||||
The calculated fair value of the Cipkowski options was $0.156 per share. The fair value of the Cipkowski option grant was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 4.34%, expected life of 10 years; and stock price volatility of 69%. The value of the Cipkowski grant totaled $78,000, which the Company recognized in share-based payment expense amortized over the required service period of 3 years. The Company recognized $0 in share based payment expense for this grant in Fiscal 2013 and $13,000 in share-based payment expense for this grant in Fiscal 2012. As of December 31, 2013, there was $0 in unrecognized expense and 0 months remaining. | |||||||||||||||||
Stock option activity for Fiscal 2013 and Fiscal 2012 is summarized as follows: (the figures contained within the tables below have been rounded to the nearest thousand) | |||||||||||||||||
Year Ended December 31, | Year Ended December 31, | ||||||||||||||||
2013 | 2012 | ||||||||||||||||
Shares | Weighted | Shares | Weighted | ||||||||||||||
Average Exercise | Average Exercise | ||||||||||||||||
Price | Price | ||||||||||||||||
Options outstanding at beginning of year | 2,939,000 | $ | 0.69 | 2,699,000 | $ | 0.76 | |||||||||||
Granted | 902,000 | $ | 0.13 | 750,000 | $ | 0.18 | |||||||||||
Exercised | 0 | NA | 0 | NA | |||||||||||||
Cancelled/expired | -525,000 | $ | 0.64 | -510,000 | $ | 1.06 | |||||||||||
Options outstanding at end of year | 3,316,000 | $ | 0.44 | 2,939,000 | $ | 0.56 | |||||||||||
Options exercisable at end of year | 2,747,000 | $ | 0.49 | 2,189,000 | $ | 0.69 | |||||||||||
The following table presents information relating to stock options outstanding as of December 31, 2013: | |||||||||||||||||
Options Outstanding | Options Exercisable | ||||||||||||||||
Weighted | Weighted | Weighted | |||||||||||||||
Average | Average | Average | |||||||||||||||
Range of Exercise | Exercise | Remaining | Exercise | ||||||||||||||
Price | Shares | Price | Life in Years | Shares | Price | ||||||||||||
$0.07 - $0.20 | 2,220,000 | $ | 0.16 | 7.73 | 1,753,000 | $ | 0.16 | ||||||||||
$0.26 - $0.85 | 137,000 | $ | 0.41 | 7.16 | 35,000 | $ | 0.85 | ||||||||||
$0.86 - $1.09 | 874,000 | $ | 1.05 | 0.67 | 874,000 | $ | 1.05 | ||||||||||
$1.14 - $1.74 | 85,000 | $ | 1.52 | 0.13 | 85,000 | $ | 1.52 | ||||||||||
TOTAL | 3,316,000 | $ | 0.44 | 5.65 | 2,747,000 | $ | 0.49 | ||||||||||
As of December 31, 2013 there were 8,000 options issued and outstanding under the 2000 Plan and 3,307,000 options issued and outstanding under the 2001 Plan, for a total of 3,316,000 options issued and outstanding as of December 31, 2013. Of the total options issued and outstanding, 2,747,000 are fully vested as of December 31, 2013. Intrinsic value of vested options as of December 31, 2013 was insignificant. As of December 31, 2013, there were 409,000 options available for issuance under the 2001 Plan and 4,000,000 options available for issuance under the 2013 Plan. | |||||||||||||||||
[3] Warrants: As of December 31, 2013 and December 31, 2012 there were 3,303,000 and 375,000 warrants outstanding, respectively. Any common shares issued as a result of the exercise of warrants would be new common shares issued from our authorized issued shares. | |||||||||||||||||
In connection with their services as placement agent in the Company’s Series A Debenture offering, on July 17, 2008, the Company issued Cantone Research, Inc. (“Cantone”) a four-year warrant to purchase 30,450 shares of the Company’s common stock at an exercise price of $0.37 per share, and on August 4, 2008 issued Cantone a four-year warrant to purchase 44,550 shares of the Company’s common stock at an exercise price of $0.40 per share. All warrants issued to Cantone were immediately exercisable upon issuance. The closing price of the Company’s common shares was $0.37 and $0.40 on July 17, 2008 and August 4, 2008, respectively. The July 17, 2008 warrants were valued using the Black Scholes pricing model and the following assumptions, dividend yield of zero, volatility of 46.0%, risk free interest rate of 4.7%, and expected life of 4 years. The August 4, 2008 warrants were valued using the Black Scholes pricing model and the following assumptions, dividend yield of zero, volatility of 46.1%, risk free interest rate of 4.6% and expected life of 4 years. The total value of the Cantone warrants was $12,000, which was recognized as financing costs and was amortized over the term of the Series A Debentures, with $0 in expense being recognized in Fiscal 2013 and $2,000 in expense being recognized in Fiscal 2012. As of December 31, 2013, there was $0 in unrecognized expense and 0 months remaining. | |||||||||||||||||
The Cantone warrants were amended on July 31, 2012 in connection with the extension and amendment of the Series A Debentures; more specifically they were amended to reflect an exercise price of $0.17 per shares and a new term of three years (see Note E – Long-term Debt). The Cantone warrants are exercisable through July 31, 2015 (see Part I, Item I, Note E). The fair value of the Cantone warrants was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 1.51; expected life of 3 years; and stock price volatility of 77%. The value of the Cantone warrant was $12,000 and the Company recognized $12,000 (or the full expense) in share based payment expense in Fiscal 2012. | |||||||||||||||||
On August 1, 2012, we entered into a Consulting Agreement (“Consulting Agreement”) with Cantone Asset Management, LLC (“CAM”). The Consulting Agreement commenced August 1, 2012 and ended on August 1, 2013. Under the terms of the Consulting Agreement, CAM provided the Company with financial advisory services and advice related to debt refinancing. On August 1, 2012, the Company issued CAM warrants to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.16 per share (the closing price of the Company’s common shares on August 1, 2012) (the “CAM Warrant”). The CAM Warrant is exercisable through July 31, 2015 and has piggyback registration rights. The fair value of the CAM Warrants was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 1.56; expected life of 3 years; and stock price volatility of 77%. The value of the CAM Warrant was $48,000 and the Company recognized $48,000 (or the full expense) in share based payment expense in Fiscal 2012. | |||||||||||||||||
On January 16, 2013, in connection with the Imperium Line of Credit, the Company granted Imperium a 7-year warrant to purchase 2,000,000 common shares of the Company at an exercise price of $0.18, the closing price of our common shares on January 16, 2013 (the “Imperium Warrant”). The Imperium Warrant was 100% (or 2,000,000 common shares) exercisable on the date of issuance. The fair value of the Imperium Warrant is $290,000 and was estimated using the Black-Scholes pricing model using the following weighted average assumptions: dividend yield of 0%; risk-free interest rate of 1.84; expected life of 7 years; and stock price volatility of 82%. The Company is capitalizing this cost as deferred financing cost amortized over the term of the Imperium LSA (3 years). The Company amortized $97,000 of this debt discount cost in Fiscal 2013 and $0 in deferred financing cost in Fiscal 2012 (as the Imperium Warrant was not issued until January 2013). As of December 31, 2013, there was $193,000 in unrecognized cost related to the Imperium Warrant with 24 months remaining. | |||||||||||||||||
On January 16, 2013, as part of their finder’s fee compensation, the Company issued Monarch Capital Group, LLC (“Monarch”) a 5-year warrant representing 3% of the Imperium Warrant, or a 5-year warrant to purchase 60,000 common shares of the Company, also at a strike price of $0.18, the closing price of our common shares on January 16, 2013 (the “Monarch Warrant”). The Monarch Warrant was 100% (or 60,000 common shares) exercisable on the date of issuance. The fair value of the Monarch Warrant is $9,000 and was estimated using the Black-Scholes pricing model using the following weighted average assumptions: dividend yield of 0%; risk-free interest rate of 1.84; expected life of 5 years; and stock price volatility of 82%. The Company is capitalizing this cost as deferred financing cost amortized over the term of the Imperium LSA, or over 36 months. The Company amortized $3,000 of this deferred financing cost in Fiscal 2013 and $0 in deferred financing cost in Fiscal 2012 (as the Monarch Warrant was not issued until January 2013). As of December 31 2013, there was $6,000 in unrecognized deferred financing cost related to the Monarch Warrant with 24 months remaining. | |||||||||||||||||
On October 7, 2013, we entered into a new Placement Agent Agreement (“2013 Agent Agreement”) with CRI related to the further extension of the Series A Debentures, as amended, due August 1, 2013. Under the terms of the 2013 Agent Agreement, CRI acted as our exclusive placement agent in connection with an amendment of the Series A Debentures. Under the amendment, the term of Series A Debentures was extended to reflect a due date of either February 1, 2014 or August 1, 2014, at the election of the Series A Debenture Holder. The interest rate during the extension period remains 15% per annum, due quarterly in arrears. All other terms of the Series A Debentures remain the same. | |||||||||||||||||
As compensation for their placement agent services in an October 2013 extension of the Series A Debentures, on October 7, 2013 Cantone received a 3-year warrant to purchase 75,000 common shares at an exercise price of $0.14 (the average closing sale price of our common shares for the 5 days business days ending October 7, 2013). The fair value of the Cantone warrant was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 2.65; expected life of 10 years; and stock price volatility of 73%. The value of the Cantone warrant was $10,000 and the Company recognized 100% of this expense on the date of the grant, or $10,000 in Fiscal 2013. | |||||||||||||||||
On October 7, 2013, we entered into a new $200,000 Bridge Loan (the “2013 Bridge Loan”) with CAM to pay off the existing Bridge Loan with CAM and to pay placement agent fees and expenses. The maturity date of the 2013 Bridge Loan is August 1, 2014 and it bears simple interest in advance of 15% to be paid in the form of 300,000 shares of restricted shares of ABMC common stock. In addition to the interest, as inducement to enter into the 2013 Bridge Loan, we issued 153,486 restricted shares of ABMC common stock to CAM, and we issued CAM a 3-year warrant to purchase 250,000 common shares at an exercise price of $0.14 (the average closing sale price of our common shares for the 5 days business days ending October 7, 2013). The warrants are 100% exercisable on the date of the grant. The fair value of the CAM warrant was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 2.65; expected life of 10 years; and stock price volatility of 73%. The value of the warrant was $35,000 and the Company recognized 100% of this expense on the date of the grant, or $35,000 in Fiscal 2013. | |||||||||||||||||
On October 7, 2013, we entered into another Agreement to the Series A Debenture (the “2013 Series A Debenture Amendment”) with thirty of the thirty-two holders of Series A Debentures (the “Debenture Holders”) (representing $634,500 of Series A Debentures). One of the Debenture Holders (representing $10,500 in Series A Debentures) did not wish to extend and we used cash on hand and net proceed from another bridge loan with CAM to pay the principal amount due to this Holder. One of the Debenture Holders transferred their investment to another existing Debenture Holder. An extension period of either 6 or 12 months was at the election of the Debenture Holder. 27 of the 30 Debenture Holders (representing $543,500 of Series A Debentures) elected to extend for a period of 12 months. The other 3 (representing $91,000 in Series A Debentures) elected to extend for a period of 6 months. The 27 Holders that elected to extend for a 12-month period were each issued a warrant to purchase 1 share of common stock for each $1.00 that was extended. We issued 2-year warrants to purchase 543,500 shares of ABMC common stock at an exercise price of $0.14 (the average closing sale price of our common shares for the 5 days business days ending October 7, 2013) to these 27 Holders (the “2013 Holder Warrants”). The fair value of the Debenture Holder warrants was estimated utilizing the Black-Scholes option-pricing model. The following weighted average assumptions were used: dividend yield of 0%; risk-free interest rate of 2.65; expected life of 10 years; and stock price volatility of 73%. The value of the warrants was $76,000 and the Company is amortizing this cost over the term of the Series A Debenture extension, or 12 months. The Company recognized $32,000 in expense in Fiscal 2013. As of December 31, 2013, there was $44,000 in unrecognized debt issuance expense with 7 months remaining. | |||||||||||||||||
COMMITMENTS_CONTINGENCIES_AND_
COMMITMENTS, CONTINGENCIES AND OTHER MATTERS | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Commitments and Contingencies Disclosure [Abstract] | ' | ||||
Commitments and Contingencies Disclosure [Text Block] | ' | ||||
NOTE J – COMMITMENTS, CONTINGENCIES AND OTHER MATTERS | |||||
[1] Operating leases: The Company leases office and R&D/production facilities in New Jersey under long-term, non-cancellable operating leases. In December 2013, the Company extended the lease for the New Jersey facility for an additional 12 months, or through December 31, 2014. The future minimum rent due in 2014 under the lease extension is $90,000. The Company also leases office support equipment through October 2014. The future minimum rental payment due in 2014 under the support equipment-operating lease is $5,000. At December 31, 2013, the future minimum rental payments under these operating leases are as follows: | |||||
2014 | $ | 95,000 | |||
$ | 95,000 | ||||
Rent expense was $122,000 in both Fiscal 2013 and Fiscal 2012. | |||||
[2] Employment agreements: On October 30, 2013, Melissa A. Waterhouse was appointed as the Company’s Interim Chief Executive Officer and Chief Financial Officer after the Company was notified that Stan Cipkowski was unable to continue serving as the Company’s Chief Executive Officer/Chief Financial Officer for medical reasons (the Company was subsequently notified on November 1, 2013 that Mr. Cipkowski passed away). The Company entered into a new Employment Agreement with Waterhouse on November 6, 2013 (the Company previously entered into an Employment Agreement with Waterhouse in April 2012 as Executive Vice President of the Company). The agreement provides for a $140,000 annual salary and is for a term of one year. It automatically renews unless either party gave advance notice of 60 days. The employment agreement contains severance provisions; in the event the Company terminates Waterhouse’s employment for any reason other than cause (which is defined under the employment agreement), Waterhouse would receive severance pay equal to 12 months of her base salary at the time of termination, with continuation of all medical benefits during the twelve-month period at the Company’s expense. In addition, Waterhouse may tender her resignation and elect to exercise the severance provision if she is required to relocate more than 50 miles from the Company’s New York facility as a continued condition of employment, if there is a substantial change in the responsibilities normally assumed by her position, or if she is asked to commit or conceal an illegal act by an officer or member of the board of directors of the Company. In the case of a change in control of the Company, Waterhouse would be entitled to severance pay equal to two times her base salary under certain circumstances. | |||||
Until November 1, 2013, there was an employment agreement in place between the Company and Stan Cipkowski (‘Cipkowski”) as Chief Executive Officer. The agreement provided for a $206,000 annual salary. And also has the same severance provisions as the Waterhouse employment agreement. | |||||
[3] Legal: On December 16, 2010, the Company filed a complaint in the Supreme Court of the State of New York in Columbia County against Martin R. Gould (“Gould”), Jacqueline Gale (“Gale”), Advanced Diagnosticum Products, Inc. (“ADPI”) and Biosure, Inc. (“Biosure”), together the “Defendants”. The complaint alleged that Gould, the Company’s former Chief Science Officer and Executive Vice President of Technology, and Gale, the Company’s former Vice President of Manufacturing and Development, were performing illegal, competitive, employment-related services for ADPI and Biosure during their employment with the Company, were using Company resources to perform such services, and were doing so in their capacity as employees and/or officers of ADPI and Biosure. Because the Defendants continued to engage in illegal activity, in addition to the compensatory and punitive damages noted below, the complaint also sought an injunction restraining the Defendants from engaging in further wrongdoing. The Defendants exercised their right to move the action to federal court in the United States District Court for the District of New Jersey. In March 2011, defendant Gould filed a counter-claim against the Company in the amount of $150,000 alleging breach of contract related to an employment agreement between Gould and the Company. | |||||
On August 8, 2013, court-ordered mediation was held resulting in settlement between all parties. All parties agreed that the matter was resolved in order to avoid the costs and uncertainties of litigation, with no admissions of guilt from any of the parties involved. All parties were released discharged from any and all claims, injuries, rights, liabilities and causes of action of every nature and description whatsoever, both statutory and common law, known or unknown, that spring from the facts alleged or that could have been alleged either as claims, cross claims, third party claims, or affirmative defenses in the litigation. Under the terms of the settlement, each party has agreed not to disclose to any third parties the terms and conditions of the settlement agreement. | |||||
As previously disclosed, the Company received a warning letter from the FDA in July 2009 that alleged the Company was marketing its point of collection oral fluid drug test, OralStat, in workplace settings without marketing clearance or approval. A warning letter is considered by FDA to be informal and advisory. While a warning letter communicates FDA’s position on a matter it does not commit the FDA to taking enforcement action. The Company communicated to the FDA its belief (based on legal opinion) that marketing clearance was not required in non-clinical markets. The FDA continued to disagree with the Company’s interpretation of FDA regulations related to medical devices, and the FDA continued to assert jurisdiction of drug testing performed in the workplace. The Company also advised FDA that the Company was willing to obtain marketing clearance but that specific technical and scientific issues existed when attempting to utilize FDA’s draft guidance for our OralStat (because the draft guidance was written for urine drug tests). Nevertheless, the Company was unable to reach a consensus with the FDA on neither the jurisdiction issue nor the technical issues. | |||||
On July 10, 2012, the Company entered into a Consent Decree of Permanent Injunction (the “Consent Decree”) with FDA. Under the terms of the Consent Decree, the Company was allowed to continue to market its OralStat drug test in the workplace market while the Company took action to obtain a 510(k) marketing clearance. More specifically, FDA will provide the Company with its most recent guidance on the clinical and analytical studies that need to be conducted to gather data in support of a 510(k) submission for OralStat. The Company then had a total of 396 days to discuss protocols with FDA, complete our analytical and clinical studies and submit a substantially complete 510(k). The Company agreed to withdraw the OralStat product from the workplace market if any of the following events occurred: 1) the Company did not submit a substantially complete 510(k) within the specified time period, 2) the Company failed to submit additional information within time frames specified by FDA, 3) the Company withdraw its submission, or 4) the Company’s 510(k) submission results in FDA’s determination that the product was not substantially equivalent. On August 3, 2012 the Consent decree was approved and entered by the United States District Court for the Northern District of New York, and on August 3, 2012, the Company received guidance from FDA. On September 3, 2013, the Company filed its application for 510(k) marketing clearance as required under the Consent Decree, and on September 18, 2013 the Company was notified that an administrative acceptance review was conducted, and the Company’s 510(k) marketing application was found to contain all of the necessary elements and information needed to proceed with the substantive review. In November 2013, the Company was informed that the FDA determined that the Company’s OralStat was not substantially equivalent to the predicate market device. In accordance with the Consent Decree, the Company ceased marketing and selling OralStat to the workplace (non-forensic) market. | |||||
In addition, from time to time, the Company is named in legal proceedings in connection with matters that arose during the normal course of business. While the ultimate result of any such litigation cannot be predicted, if the Company is unsuccessful in defending any such litigation, the resulting financial losses could have an adverse effect on the financial position, results of operations and cash flows of the Company. The Company is not aware of any significant litigation loss contingencies for which management believes it is both probable that a liability has been incurred and that the amount of the loss can be reasonably estimated. | |||||
RELATED_PARTY_DISCLOSURES
RELATED PARTY DISCLOSURES | 12 Months Ended |
Dec. 31, 2013 | |
Related Party Transactions [Abstract] | ' |
Related Party Transactions Disclosure [Text Block] | ' |
NOTE K – Related Party Disclosures | |
Edmund M. Jaskiewicz | |
During Fiscal 2013 and Fiscal 2012, the Company paid an aggregate of $5,000 and $10,000, respectively, to Edmund M. Jaskiewicz, the Company’s President and Chairman of the Board of Directors (“Jaskiewicz”) in consideration of his services as patent and trademark counsel to the Company, services as a member of its Board of Directors, and for reimbursement of expenses related to same. At December 31, 2013, there were invoices totaling $32,000 payable to Jaskiewicz. | |
As a condition to the Rosenthal Line of Credit closing, in June 2009, Jaskiewicz was required to execute an Agreement of Subordination and Assignment (“Subordination Agreement”) related to $124,000 owed to Jaskiewicz by the Company as of June 29, 2009 (the “Jaskiewicz Debt”). Under the Subordination Agreement, the Jaskiewicz Debt is not payable, is junior in right to the Rosenthal Line of Credit and no payment may be accepted or retained by Jaskiewicz unless and until the Company has paid and satisfied in full any obligations to Rosenthal. Furthermore, the Jaskiewicz Debt was assigned and transferred to Rosenthal as collateral for the Rosenthal Line of Credit. | |
As compensation for his execution of a Subordination Agreement, on July 1, 2009, July 1, 2010 and July 1, 2011, Jaskiewicz was awarded an option grant representing 50,000 common shares each year for a total of 150,000 common shares of the Company under the Company’s 2001 Plan, at an exercise price of $0.20, $0.07 and $0.13 respectively. The exercise price represents the closing price of the Company’s common shares on the date of the grant. All option grants were immediately exercisable on the date of the grant. | |
Jaskiewicz was also required to sign the same Subordination Agreement in connection with the Medallion Line of Credit and the Imperium Line of Credit. As compensation for his execution of these subsequent Subordination Agreements, on April 20, 2012, Jaskiewicz was awarded an option grant representing 150,000 common shares of the Company under the Company’s Fiscal 2001 stock option plan, at an exercise price of $0.18, the closing price of the Company’s common shares on the date of the grant. The option grant vests over 36 months as follows: 49,500 common shares on April 20, 2013, 49,500 common shares on April 20, 2014 and 51,000 common shares on April 20, 2015. | |
ALEC CIPKOWSKI | |
During Fiscal 2013, the Company paid an aggregate of $52,000, and in Fiscal 2012, the Company paid an aggregate of $60,000 to Alec Cipkowski. In August 2013, the Company reduced his compensation by 20%, or to $48,000 on an annualized basis. Alec Cipkowski is the son of the Company’s former Chief Executive Officer, Stan Cipkowski. Alec Cipkowski performs information technology services for the Company updating and maintaining the Company website as well as supporting the Rapid Reader products that are currently being used by customers. He receives normal employee benefits in accordance with the Company’s standard policies. Due to the timing of pay periods, at December 31, 2013 the Company owed Alec Cipkowski approximately $1,000, however, this amount was subsequently paid in the first regularly scheduled payroll in the year ending December 31, 2014. | |
SUBSEQUENT_EVENTS
SUBSEQUENT EVENTS | 12 Months Ended |
Dec. 31, 2013 | |
Subsequent Events [Abstract] | ' |
Subsequent Events [Text Block] | ' |
NOTE L – SUBSEQUENT EVENTS | |
On January 17, 2014, the Company entered into a Financial Advisory Agreement (the “Agreement”) with Landmark Financial Corporation (‘Landmark”). The Agreement provides that Landmark will provide certain financial advisory services for a minimum period of 6 months, and as consideration for these services, the Company will pay Landmark (a) a retainer fee consisting of 208,333 restricted shares of common stock and (b) a “success fee” for the consummation of each and any transaction closing during the term of the Agreement and for 24 months thereafter, between the Company and any party first introduced to the Company by Landmark, or for any other transaction not originated by Landmark but for which Landmark provides substantial support in completing during the term of the Agreement. There is no material relationship between the Company and Landmark, other than with respect to the Agreement. The Company issued 208,333 restricted shares of common stock to Landmark on January 28, 2014. | |
The Company’s Mortgage Consolidation Loan with First Niagara matured on March 1, 2014. As of the date of this filing, the Company is discussing an extension of the Mortgage Consolidation Loan with First Niagara. | |
SEGMENT_AND_GEOGRAPHIC_INFORMA
SEGMENT AND GEOGRAPHIC INFORMATION | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Segment Reporting [Abstract] | ' | |||||||
Segment Reporting Disclosure [Text Block] | ' | |||||||
NOTE M- SEGMENT AND GEOGRAPHIC INFORMATION | ||||||||
The Company operates in one reportable segment. | ||||||||
Information concerning net sales by principal geographic location is as follows: | ||||||||
Year Ended | Year Ended | |||||||
December 31, | December 31, | |||||||
2013 | 2012 | |||||||
United States | $ | 8,158,000 | $ | 8,405,000 | ||||
North America (not domestic) | 197,000 | 430,000 | ||||||
Europe | 174,000 | 343,000 | ||||||
Asia/Pacific Rim | 66,000 | 50,000 | ||||||
South America | 297,000 | 115,000 | ||||||
Africa | 2,000 | 0 | ||||||
$ | 8,894,000 | $ | 9,343,000 | |||||
The_Company_and_its_Significan1
The Company and its Significant Accounting Policies (Policies) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Accounting Policies [Abstract] | ' | |||||||
Cash and Cash Equivalents, Policy [Policy Text Block] | ' | |||||||
[1] Cash equivalents: The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. | ||||||||
Trade and Other Accounts Receivable, Policy [Policy Text Block] | ' | |||||||
[2] Accounts Receivable: Accounts receivable consists of mainly trade receivables due from customers for the sale of our products. Payment terms vary on a customer-by-customer basis, and currently range from cash on delivery to net 60 days. Receivables are considered past due when they have exceeded their payment terms. Accounts receivable have been reduced by an estimated allowance for doubtful accounts. The Company estimates its allowance for doubtful accounts based on facts, circumstances and judgments regarding each receivable. Customer payment history and patterns, historical losses, economic and political conditions, trends and individual circumstances are among the items considered when evaluating the collectability of the receivables. Accounts are reviewed regularly for collectability and those deemed uncollectible are written off. At December 31, 2013 and December 31, 2012 the Company had an allowance for doubtful accounts of $58,000 and $60,000, respectively. | ||||||||
Inventory, Policy [Policy Text Block] | ' | |||||||
[3] Inventory: Inventory is stated at the lower of cost or market. Work in process and finished goods are comprised of labor, overhead and raw material costs. Labor and overhead costs are determined on a rolling average cost basis and raw materials are determined on an average cost basis. At December 31, 2013 and December 31, 2012, the Company established an allowance for slow moving and obsolete inventory of $399,000 and $261,000, respectively. | ||||||||
Income Tax, Policy [Policy Text Block] | ' | |||||||
[4] Income taxes: The Company follows ASC 740 “Income Taxes” (“ASC 740”) which prescribes the asset and liability method whereby deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted laws and tax rates that will be in effect when the differences are expected to reverse. The measurement of deferred tax assets is reduced, if necessary, by a valuation allowance for any tax benefits that are not expected to be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. Under ASC 740, tax benefits are recorded only for tax positions that are more likely than not to be sustained upon examination by tax authorities. The amount recognized is measured as the largest amount of benefit that is greater than 50 percent likely to be realized upon ultimate settlement. Unrecognized tax benefits are tax benefits claimed in the Company’s tax returns that do not meet these recognition and measurement standards. | ||||||||
Depreciation, Depletion, and Amortization [Policy Text Block] | ' | |||||||
[5] Depreciation and amortization: Property, plant and equipment are depreciated on the straight-line method over their estimated useful lives; generally 3-5 years for equipment and 30 years for buildings. Leasehold improvements and capitalized lease assets are amortized by the straight-line method over the shorter of their estimated useful lives or the term of the lease. Intangible assets include the cost of patent applications, which are deferred and charged to operations over 19 years. The accumulated amortization of patents is $158,000 and $156,000 at December 31, 2013 and December 31, 2012, respectively. Annual amortization expense of such intangible assets is expected to be $2,000 per year for the next 5 years. | ||||||||
Revenue Recognition, Policy [Policy Text Block] | ' | |||||||
[6] Revenue recognition: The Company recognizes revenue when title transfers upon shipment. Sales are recorded net of discounts and returns. All buyers have economic substance apart from the Company and the Company does not have any obligation for customer acceptance. The Company's price is fixed and determinable at the date of sale. The buyer has paid the Company or is obligated to pay the Company or, in the case of a distributor, the obligation is not contingent on the resale of the product, nor does the Company have any obligation to bring about the resale of the product. The buyer's obligation would not be changed in the event of theft or physical destruction or damage to the product. All distributors have economic substance apart from the Company and their own customers and payment terms are not conditional. The transactions with distributors are on terms similar to those given to the Company's other customers. No agreements exist with the distributors that offer a right of return. | ||||||||
Shipping and Handling Cost, Policy [Policy Text Block] | ' | |||||||
[7] Shipping and handling: Shipping and handling fees charged to customers are included in net sales, and shipping and handling costs incurred by the Company, to the extent of those costs charged to customers, are included in cost of sales. | ||||||||
Research and Development Expense, Policy [Policy Text Block] | ' | |||||||
[8] Research and development: Research and development (“R&D”) costs are charged to operations when incurred. These costs include salaries, benefits, travel, supplies, depreciation of R&D equipment and other miscellaneous expenses. | ||||||||
Earnings Per Share, Policy [Policy Text Block] | ' | |||||||
[9] Net loss per common share: Basic loss per common share is calculated by dividing net loss by the weighted average number of outstanding common shares during the period. | ||||||||
Potential common shares outstanding as of December 31, 2013 and 2012: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
Warrants | 3,303,000 | 375,000 | ||||||
Options | 3,316,000 | 2,939,000 | ||||||
For Fiscal 2013 and Fiscal 2012, the number of securities not included in the diluted loss per share was 6,619,000 and 3,314,000, respectively, as their effect was anti-dilutive. | ||||||||
Use of Estimates, Policy [Policy Text Block] | ' | |||||||
[10] Use of estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Our management believes the major estimates and assumptions impacting our financial statements are the following: | ||||||||
⋅ | estimates of the fair value of stock options and warrants at date of grant; and | |||||||
⋅ | estimates of the inventory reserves; and | |||||||
⋅ | estimates and evaluation of litigation being pursued. | |||||||
The fair value of stock options and warrants issued to employees, members of our Board of Directors, consultants and in connection with debt financings is estimated on the date of grant based on the Black-Scholes options-pricing model utilizing certain assumptions for a risk free interest rate; volatility; and expected remaining lives of the awards. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management judgment. | ||||||||
As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company's forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the amount of vested options as a percentage of total options outstanding. | ||||||||
If the Company's actual forfeiture rate is materially different from its estimate, or if the Company reevaluates the forfeiture rate in the future, the equity-based compensation expense could be significantly different from what we have recorded in the current period. | ||||||||
Actual results may differ from estimates and assumptions of future events. | ||||||||
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] | ' | |||||||
[11] Impairment of long-lived assets: The Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that the assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. | ||||||||
Fair Value of Financial Instruments, Policy [Policy Text Block] | ' | |||||||
[12] Financial Instruments: The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and other liabilities approximate their fair value based on the short term nature of those items. | ||||||||
Estimated fair value of financial instruments is determined using available market information. In evaluating the fair value information, considerable judgment is required to interpret the market data used to develop the estimates. The use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts. | ||||||||
Accordingly, the estimates of fair value presented herein may not be indicative of the amounts that could be realized in a current market exchange. | ||||||||
ASC Topic 820, “Fair Value Measurements and Disclosures” (“ASC Topic 820”) establishes a hierarchy for ranking the quality and reliability of the information used to determine fair values. ASC Topic 820 requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories: | ||||||||
Level 1: Unadjusted quoted market prices in active markets for identical assets or liabilities. | ||||||||
Level 2: Unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices are observable for the asset or liability. | ||||||||
Level 3: Unobservable inputs for the asset or liability. | ||||||||
The Company endeavors to utilize the best available information in measuring fair value. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The following methods and assumptions were used by the Company in estimating its fair value disclosures for financial instruments: | ||||||||
Cash and Cash Equivalents—The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair value due to the short-term maturity of these instruments. | ||||||||
Line of Credit and Long-Term Debt—The carrying amounts of the Company’s borrowings under its line of credit agreement and other long-term debt approximates fair value, based upon current interest rates, some of which are variable interest rates. | ||||||||
Accounting For Share Based Payments And Stock Warrants [Policy Text Block] | ' | |||||||
[13] Accounting for share-based payments and stock warrants: In accordance with the provisions of ASC Topic 718, “Accounting for Stock Based Compensation”, the Company recognizes share-based payment expense for stock options and warrants. The weighted average fair value of options granted during Fiscal 2013 and Fiscal 2012 was $0.13 and $0.18, respectively. (See Note I [2] – Stockholders’ Equity) | ||||||||
The Company accounts for derivative instruments in accordance with ASC Topic 815 “Derivatives and Hedging” (“ASC Topic 815”). The guidance within ASC Topic 815 requires the Company to recognize all derivatives as either assets or liabilities on the statement of financial position unless the contract, including common stock warrants, settles in the Company’s own stock and qualifies as an equity instrument. A contract designated as an equity instrument is included in equity at its fair value, with no further fair value adjustments required; and if designated as an asset or liability is carried at fair value with any changes in fair value recorded in the results of operations. The weighted average fair value of warrants issued was $0.17 in Fiscal 2013 and $0.16 in Fiscal 2012. (See Note I [3] – Stockholders’ Equity) | ||||||||
Concentration Risk, Credit Risk, Policy [Policy Text Block] | ' | |||||||
[14] Concentration of credit risk: The Company sells its drug-testing products primarily to United States customers and distributors. Credit is extended based on an evaluation of the customer’s financial condition. | ||||||||
At December 31, 2013, one customer accounted for 39.7% of the Company’s net accounts receivable. A substantial portion of this balance was collected in the first quarter of the year ending December 31, 2014. Due to the longstanding nature of our relationships with these customers and contractual obligations, the Company is confident that it will recover these amounts. | ||||||||
At December 31, 2012, three customers accounted for 12.8%, 9.7% and 9.6% of the Company’s net accounts receivable. A substantial portion of these balances was collected in the first quarter of the year ending December 31, 2013. Due to the longstanding nature of our relationships with these customers and contractual obligations, the Company is confident that it will recover these amounts. | ||||||||
The Company has established an allowance for doubtful accounts of $58,000 and $60,000 at December 31, 2013 and December 31, 2012, respectively, based on factors surrounding the credit risk of our customers and other information. | ||||||||
One of the Company’s customers accounted for approximately 15.5% of net sales of the Company in Fiscal 2013 and 14.8% of net sales of the Company in Fiscal 2012. | ||||||||
The Company maintains certain cash balances at financial institutions that are federally insured and at times the balances have exceeded federally insured limits. | ||||||||
Comprehensive Income, Policy [Policy Text Block] | ' | |||||||
[15] Reporting comprehensive income: The Company reports comprehensive income in accordance with the provisions of ASC Topic 220, “Reporting Comprehensive Income” (“ASC Topic 220”). The provisions of ASC Topic 220 require the Company to report the change in the Company's equity during the period from transactions and events other than those resulting from investments by, and distributions to, the shareholders. For Fiscal 2013 and Fiscal 2012, comprehensive income was the same as net income. | ||||||||
Reclassification, Policy [Policy Text Block] | ' | |||||||
[16] Reclassifications: Certain items have been reclassified from the prior years to conform to the current year presentation. | ||||||||
New Accounting Pronouncements, Policy [Policy Text Block] | ' | |||||||
[17] New accounting pronouncements: There were no new standards adopted in Fiscal 2013 that materially impacted the Company’s financial statements. | ||||||||
The_Company_and_its_Significan2
The Company and its Significant Accounting Policies (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Accounting Policies [Abstract] | ' | |||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | ' | |||||||
Potential common shares outstanding as of December 31, 2013 and 2012: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
Warrants | 3,303,000 | 375,000 | ||||||
Options | 3,316,000 | 2,939,000 | ||||||
INVENTORY_Tables
INVENTORY (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Inventory Disclosure [Abstract] | ' | |||||||
Schedule of Inventory, Current [Table Text Block] | ' | |||||||
Inventory is comprised of the following: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
Raw Materials | $ | 1,434,000 | $ | 1,578,000 | ||||
Work In Process | 758,000 | 671,000 | ||||||
Finished Goods | 278,000 | 583,000 | ||||||
Allowance for slow moving and obsolete inventory | -399,000 | -261,000 | ||||||
$ | 2,071,000 | $ | 2,571,000 | |||||
PROPERTY_PLANT_AND_EQUIPMENT_T
PROPERTY, PLANT AND EQUIPMENT (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Property, Plant and Equipment [Abstract] | ' | |||||||
Property, Plant and Equipment [Table Text Block] | ' | |||||||
Property, plant and equipment, at cost, are as follows: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
Land | $ | 102,000 | $ | 102,000 | ||||
Buildings and improvements | 1,363,000 | 1,363,000 | ||||||
Manufacturing and warehouse equipment | 2,601,000 | 2,589,000 | ||||||
Office equipment (incl. furniture and fixtures) | 412,000 | 409,000 | ||||||
4,478,000 | 4,463,000 | |||||||
Less accumulated depreciation | -3,388,000 | -3,271,000 | ||||||
$ | 1,090,000 | $ | 1,192,000 | |||||
ACCRUED_EXPENSES_AND_OTHER_CUR1
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Payables and Accruals [Abstract] | ' | |||||||
Schedule Of Accrued Expenses And Other Current Liabilities [Table Text Block] | ' | |||||||
Accrued expenses and other current liabilities consisted of the following: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
Accrued accounting fees | $ | 65,000 | $ | 40,000 | ||||
Accrued interest payable | 35,000 | 29,000 | ||||||
Accounts receivable credit balances | 24,000 | 27,000 | ||||||
Accrued sales tax payable | 89,000 | 42,000 | ||||||
Accrued expenses | 26,000 | 24,000 | ||||||
Other current liabilities | 75,000 | 12,000 | ||||||
$ | 314,000 | $ | 174,000 | |||||
LONGTERM_DEBT_Tables
LONG-TERM DEBT (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Debt Disclosure [Abstract] | ' | |||||||
Schedule of Long-term Debt Instruments [Table Text Block] | ' | |||||||
Long-term debt consisted of the following: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
First Niagara: | ||||||||
Mortgage payable in equal monthly installments of $14,000 including interest at 9.25% through March 1, 2014 (“Maturity”) with a final lump sum payment representing the entire unpaid balance of principal, plus accrued interest at Maturity, collateralized by the building, land and personal property(1) | $ | 452,000 | $ | 608,000 | ||||
MARLIN: | ||||||||
Capital lease payable in equal monthly installment of $147 including interest at 14.46% through September 1, 2013 | 0 | 1,000 | ||||||
Debenture financing(2): | ||||||||
$634,000 in principal amount of Series A Debentures; interest at 15% per annum from August 1, 2013 through August 1, 2014, payable quarterly with first payment due November 1, 2013; maturity date of August 1, 2014 | 634,000 | 645,000 | ||||||
Bridge Loan with Cantone Asset Management, LLC(3): | ||||||||
Interest rate of 15% payable upon loan maturity; maturity date of August 1, 2014. | 200,000 | 150,000 | ||||||
1,286,000 | 1,404,000 | |||||||
Less debt discount (Debenture financing) | -60,000 | 0 | ||||||
Total current debt | $ | 1,226,000 | $ | 1,404,000 | ||||
-1 | The mortgage through First Niagara was refinanced and extended on March 8, 2013. | |||||||
-2 | The original debt with the Series A Debenture Holders was $750,000, with an interest rate of 10% per annum. It was payable semi-annually in August and February of each year with the first payment due February 1, 2009 and a maturity date of August 1, 2012. In July 2012, the Series A Debentures were amended and extended; under the amendment and extension the interest rate from August 1, 2012 through December 31, 2012 was increased to 15% per annum (the interest rate from January 1, 2012 through July 31, 2012 remained at 10%), and the maturity date was extended to August 1, 2013, and $105,000 of Series A Debentures were repaid with a portion of loan proceeds from Cantone Asset Management LLC; lowering the principal of the Series A Debenture to $645,000. The Series A Debentures were amended and extended in October 2013, and the terms noted in the table above are the revised terms of the Series A Debentures. $10,000 in Series A Debentures was repaid under the extension, lowering the principal to $635,000 at December 31, 2013. Even after the amendment and extension, the Series A Debentures remained classified as a current liability given their maturity date of August 1, 2014. | |||||||
-3 | In October 2013, the Company increased our Bridge Loan with Cantone Asset Management LLC from $150,000 to $200,000. The additional $50,000 was used to pay placement agent fees of $39,750 and Cantone Research Inc’s legal fees of $4,000. The remaining proceeds (approx $6,000) were remitted to the Company and used toward the repayment of the $10,000 in non-extending Series A Debentures. | |||||||
Schedule of Maturities of Long-term Debt [Table Text Block] | ' | |||||||
At December 31, 2013, the following are the maturities of long-term debt for each of the next five years: | ||||||||
2014 | $ | 1,226,000 | ||||||
2015 | 0 | |||||||
2016 | 0 | |||||||
2017 | 0 | |||||||
2018 | 0 | |||||||
$ | 1,226,000 | |||||||
INCOME_TAXES_Tables
INCOME TAXES (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Income Tax Disclosure [Abstract] | ' | |||||||
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] | ' | |||||||
A reconciliation of the U.S. Federal statutory income tax rate to the effective income tax rate is as follows: | ||||||||
Year Ended | Year Ended | |||||||
December 31, 2013 | December 31, 2012 | |||||||
Tax expense at federal statutory rate | 34 | % | 34 | % | ||||
State tax expense, net of federal tax effect | 5 | % | 5 | % | ||||
Permanent timing differences | -10 | % | -4 | % | ||||
Deferred income tax asset valuation allowance | -29 | % | -35 | % | ||||
Effective income tax rate | 0 | % | 0 | % | ||||
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | ' | |||||||
Significant components of the Company’s deferred income tax assets are as follows: | ||||||||
December 31, 2013 | December 31, 2012 | |||||||
Inventory | $ | 15,000 | $ | 18,000 | ||||
Inventory allowance | 156,000 | 102,000 | ||||||
Allowance for doubtful accounts | 23,000 | 23,000 | ||||||
Accrued compensation | 27,000 | 27,000 | ||||||
Net operating loss carry forward expired | 0 | -197,000 | ||||||
Net operating loss carry-forward | 5,026,000 | 5,013,000 | ||||||
Total gross deferred income tax assets | 5,247,000 | 4,986,000 | ||||||
Less deferred income tax assets valuation allowance | -5,247,000 | -4,986,000 | ||||||
Net deferred income tax assets | $ | 0 | $ | 0 | ||||
STOCKHOLDERS_EQUITY_Tables
STOCKHOLDERS' EQUITY (Tables) | 12 Months Ended | ||||||||||||||||
Dec. 31, 2013 | |||||||||||||||||
Stockholders Equity Note [Abstract] | ' | ||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | ||||||||||||||||
Stock option activity for Fiscal 2013 and Fiscal 2012 is summarized as follows: (the figures contained within the tables below have been rounded to the nearest thousand) | |||||||||||||||||
Year Ended December 31, | Year Ended December 31, | ||||||||||||||||
2013 | 2012 | ||||||||||||||||
Shares | Weighted | Shares | Weighted | ||||||||||||||
Average Exercise | Average Exercise | ||||||||||||||||
Price | Price | ||||||||||||||||
Options outstanding at beginning of year | 2,939,000 | $ | 0.69 | 2,699,000 | $ | 0.76 | |||||||||||
Granted | 902,000 | $ | 0.13 | 750,000 | $ | 0.18 | |||||||||||
Exercised | 0 | NA | 0 | NA | |||||||||||||
Cancelled/expired | -525,000 | $ | 0.64 | -510,000 | $ | 1.06 | |||||||||||
Options outstanding at end of year | 3,316,000 | $ | 0.44 | 2,939,000 | $ | 0.56 | |||||||||||
Options exercisable at end of year | 2,747,000 | $ | 0.49 | 2,189,000 | $ | 0.69 | |||||||||||
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] | ' | ||||||||||||||||
The following table presents information relating to stock options outstanding as of December 31, 2013: | |||||||||||||||||
Options Outstanding | Options Exercisable | ||||||||||||||||
Weighted | Weighted | Weighted | |||||||||||||||
Average | Average | Average | |||||||||||||||
Range of Exercise | Exercise | Remaining | Exercise | ||||||||||||||
Price | Shares | Price | Life in Years | Shares | Price | ||||||||||||
$0.07 - $0.20 | 2,220,000 | $ | 0.16 | 7.73 | 1,753,000 | $ | 0.16 | ||||||||||
$0.26 - $0.85 | 137,000 | $ | 0.41 | 7.16 | 35,000 | $ | 0.85 | ||||||||||
$0.86 - $1.09 | 874,000 | $ | 1.05 | 0.67 | 874,000 | $ | 1.05 | ||||||||||
$1.14 - $1.74 | 85,000 | $ | 1.52 | 0.13 | 85,000 | $ | 1.52 | ||||||||||
TOTAL | 3,316,000 | $ | 0.44 | 5.65 | 2,747,000 | $ | 0.49 | ||||||||||
COMMITMENTS_CONTINGENCIES_AND_1
COMMITMENTS, CONTINGENCIES AND OTHER MATTERS (Tables) | 12 Months Ended | ||||
Dec. 31, 2013 | |||||
Commitments and Contingencies Disclosure [Abstract] | ' | ||||
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | ' | ||||
At December 31, 2013, the future minimum rental payments under these operating leases are as follows: | |||||
2014 | $ | 95,000 | |||
$ | 95,000 | ||||
SEGMENT_AND_GEOGRAPHIC_INFORMA1
SEGMENT AND GEOGRAPHIC INFORMATION (Tables) | 12 Months Ended | |||||||
Dec. 31, 2013 | ||||||||
Segment Reporting [Abstract] | ' | |||||||
Schedule of Segment Reporting Information, by Segment [Table Text Block] | ' | |||||||
Information concerning net sales by principal geographic location is as follows: | ||||||||
Year Ended | Year Ended | |||||||
December 31, | December 31, | |||||||
2013 | 2012 | |||||||
United States | $ | 8,158,000 | $ | 8,405,000 | ||||
North America (not domestic) | 197,000 | 430,000 | ||||||
Europe | 174,000 | 343,000 | ||||||
Asia/Pacific Rim | 66,000 | 50,000 | ||||||
South America | 297,000 | 115,000 | ||||||
Africa | 2,000 | 0 | ||||||
$ | 8,894,000 | $ | 9,343,000 | |||||
The_Company_and_its_Significan3
The Company and its Significant Accounting Policies (Details) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Employee Stock Option [Member] | ' | ' |
Earnings Per Share Basic And Diluted [Line Items] | ' | ' |
Potential common shares outstanding | 3,316,000 | 2,939,000 |
Warrant [Member] | ' | ' |
Earnings Per Share Basic And Diluted [Line Items] | ' | ' |
Potential common shares outstanding | 3,303,000 | 375,000 |
The_Company_and_its_Significan4
The Company and its Significant Accounting Policies (Details Textual) (USD $) | 1 Months Ended | 12 Months Ended | |||
Aug. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | |||
Accounting Policies [Line Items] | ' | ' | ' | ||
Net Income (Loss) Attributable to Parent, Total | ' | ($788,000) | ($1,111,000) | ||
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total | ' | 9,000 | 236,000 | ||
Cash and Cash Equivalents, Period Increase (Decrease), Total | ' | 557,000 | -4,000 | ||
Retained Earnings (Accumulated Deficit), Total | ' | 19,132,000 | 18,344,000 | ||
Allowance For Doubtful Accounts Receivable, Current | ' | 58,000 | 60,000 | ||
Inventory Adjustments, Total | ' | 399,000 | 261,000 | ||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | ' | 6,619,000 | 3,314,000 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | ' | $0.13 | $0.18 | ||
Share Based Compensation Arrangement By Share Based Payment Award Warrants Issued In Period Weighted Average Fair Value | ' | $0.17 | $0.16 | ||
Percentage Of Deferral Employee Commission | 50.00% | ' | ' | ||
Deferred Salary Payable | ' | 19,000 | ' | ||
Deferred Salary Commission | ' | 52,000 | ' | ||
Repayment Of Deferral Compensation | ' | 31,000 | ' | ||
Long-term Debt, Total | ' | 1,286,000 | 1,404,000 | ||
Effective Income Tax Rate Reconciliation, Tax Settlement, Percent, Total | ' | 50.00% | ' | ||
Amortization of Intangible Assets | ' | 2,000 | ' | ||
Patents [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Finite-Lived Intangible Asset, Useful Life | ' | '19 years | ' | ||
Amortization of Intangible Assets | ' | 158,000 | 156,000 | ||
Bridge Loan With Cantone Asset Management, Llc [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Debt Instrument, Maturity Date | ' | 1-Aug-14 | [1] | ' | |
Long-term Debt, Total | ' | 200,000 | [1] | 150,000 | [1] |
Series A Debentures [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Debt Instrument, Maturity Date | ' | 1-Aug-14 | ' | ||
Repayments of Debt | ' | 91,000 | ' | ||
Debt Instrument, Periodic Payment, Interest | ' | $544,000 | ' | ||
Executive Officer [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Warrants To Purchase Common Stock | 20.00% | ' | ' | ||
Non Executive Vice President [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Warrants To Purchase Common Stock | 20.00% | ' | ' | ||
Customer 1 [Member] | Accounts Receivable [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Concentration Risk, Percentage | ' | 39.70% | 12.80% | ||
Customer 2 [Member] | Accounts Receivable [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Concentration Risk, Percentage | ' | ' | 9.70% | ||
Customer 3 [Member] | Accounts Receivable [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Concentration Risk, Percentage | ' | ' | 9.60% | ||
Customer 4 [Member] | Sales Revenue, Goods, Net [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Concentration Risk, Percentage | ' | 15.50% | 14.80% | ||
Building [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Property, Plant and Equipment, Useful Life | ' | '30 years | ' | ||
Equipment [Member] | Maximum [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Property, Plant and Equipment, Useful Life | ' | '3 years | ' | ||
Equipment [Member] | Minimum [Member] | ' | ' | ' | ||
Accounting Policies [Line Items] | ' | ' | ' | ||
Property, Plant and Equipment, Useful Life | ' | '5 years | ' | ||
[1] | In October 2013, the Company increased our Bridge Loan with Cantone Asset Management LLC from $150,000 to $200,000. The additional $50,000 was used to pay placement agent fees of $39,750 and Cantone Research Incbs legal fees of $4,000. The remaining proceeds (approx $6,000) were remitted to the Company and used toward the repayment of the $10,000 in non-extending Series A Debentures. |
INVENTORY_Details
INVENTORY (Details) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Inventory [Line Items] | ' | ' |
Raw Materials | $1,434,000 | $1,578,000 |
Work In Process | 758,000 | 671,000 |
Finished Goods | 278,000 | 583,000 |
Allowance for slow moving and obsolete inventory | -399,000 | -261,000 |
Inventory | $2,071,000 | $2,571,000 |
PROPERTY_PLANT_AND_EQUIPMENT_D
PROPERTY, PLANT AND EQUIPMENT (Details) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Property, Plant and Equipment [Line Items] | ' | ' |
Land | $102,000 | $102,000 |
Buildings and improvements | 1,363,000 | 1,363,000 |
Manufacturing and warehouse equipment | 2,601,000 | 2,589,000 |
Office equipment (incl. furniture and fixtures) | 412,000 | 409,000 |
Property, Plant and Equipment, Gross | 4,478,000 | 4,463,000 |
Less accumulated depreciation | -3,388,000 | -3,271,000 |
Property, Plant and Equipment, Net | $1,090,000 | $1,192,000 |
PROPERTY_PLANT_AND_EQUIPMENT_D1
PROPERTY, PLANT AND EQUIPMENT (Details Textual) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Property, Plant and Equipment [Line Items] | ' | ' |
Depreciation, Total | $116,000 | $123,000 |
ACCRUED_EXPENSES_AND_OTHER_CUR2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Accrued Expenses And Other Current Liabilities [Line Items] | ' | ' |
Accrued accounting fees | $65,000 | $40,000 |
Accrued interest payable | 35,000 | 29,000 |
Accounts receivable credit balances | 24,000 | 27,000 |
Accrued sales tax payable | 89,000 | 42,000 |
Accrued expenses | 26,000 | 24,000 |
Other current liabilities | 75,000 | 12,000 |
Accrued expenses and other current liabilities | $314,000 | $174,000 |
LONGTERM_DEBT_Details
LONG-TERM DEBT (Details) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 | ||
Debt Instrument [Line Items] | ' | ' | ||
Long-term Debt | $1,286,000 | $1,404,000 | ||
Less debt discount (Debenture financing) | -60,000 | 0 | ||
Total current debt | 1,226,000 | 1,404,000 | ||
Mortgage Payable To First Niagara [Member] | ' | ' | ||
Debt Instrument [Line Items] | ' | ' | ||
Long-term Debt | 452,000 | [1] | 608,000 | [1] |
Capital Lease Payable To Marlin [Member] | ' | ' | ||
Debt Instrument [Line Items] | ' | ' | ||
Long-term Debt | 0 | 1,000 | ||
Debenture Financing [Member] | ' | ' | ||
Debt Instrument [Line Items] | ' | ' | ||
Long-term Debt | 634,000 | [2] | 645,000 | [2] |
Bridge Loan With Cantone Asset Management, Llc [Member] | ' | ' | ||
Debt Instrument [Line Items] | ' | ' | ||
Long-term Debt | $200,000 | [3] | $150,000 | [3] |
[1] | The mortgage through First Niagara was refinanced and extended on March 8, 2013. | |||
[2] | The original debt with the Series A Debenture Holders was $750,000, with an interest rate of 10% per annum. It was payable semi-annually in August and February of each year with the first payment due February 1, 2009 and a maturity date of August 1, 2012. In July 2012, the Series A Debentures were amended and extended; under the amendment and extension the interest rate from August 1, 2012 through December 31, 2012 was increased to 15% per annum (the interest rate from January 1, 2012 through July 31, 2012 remained at 10%), and the maturity date was extended to August 1, 2013, and $105,000 of Series A Debentures were repaid with a portion of loan proceeds from Cantone Asset Management LLC; lowering the principal of the Series A Debenture to $645,000. The Series A Debentures were amended and extended in October 2013, and the terms noted in the table above are the revised terms of the Series A Debentures. $10,000 in Series A Debentures was repaid under the extension, lowering the principal to $635,000 at December 31, 2013. Even after the amendment and extension, the Series A Debentures remained classified as a current liability given their maturity date of August 1, 2014. | |||
[3] | In October 2013, the Company increased our Bridge Loan with Cantone Asset Management LLC from $150,000 to $200,000. The additional $50,000 was used to pay placement agent fees of $39,750 and Cantone Research Incbs legal fees of $4,000. The remaining proceeds (approx $6,000) were remitted to the Company and used toward the repayment of the $10,000 in non-extending Series A Debentures. |
LONGTERM_DEBT_Details_1
LONG-TERM DEBT (Details 1) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Maturities Of Long Term Debt [Line Items] | ' | ' |
2014 | $1,226,000 | ' |
2015 | 0 | ' |
2016 | 0 | ' |
2017 | 0 | ' |
2018 | 0 | ' |
Long-term Debt | $1,286,000 | $1,404,000 |
LONGTERM_DEBT_Details_Textual
LONG-TERM DEBT (Details Textual) (USD $) | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 1 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 5 Months Ended | 7 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | ||||||||||||||||||||||||||||||||||||||||
Oct. 07, 2013 | Feb. 23, 2011 | Aug. 31, 2008 | Aug. 04, 2008 | Jul. 17, 2008 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2012 | Aug. 04, 2008 | Jul. 17, 2008 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 07, 2013 | Oct. 31, 2013 | Oct. 31, 2013 | Oct. 07, 2013 | Oct. 31, 2013 | Oct. 07, 2013 | Oct. 31, 2013 | Feb. 23, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Mar. 08, 2013 | Dec. 31, 2013 | Apr. 30, 2012 | 31-May-07 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 31, 2010 | Dec. 31, 2013 | Dec. 31, 2012 | Aug. 31, 2008 | Dec. 31, 2012 | Jul. 31, 2012 | Dec. 31, 2013 | Jul. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Jul. 31, 2012 | Oct. 07, 2013 | Oct. 31, 2013 | Oct. 31, 2013 | Oct. 31, 2010 | Oct. 07, 2013 | Oct. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Oct. 07, 2013 | Oct. 31, 2013 | Oct. 07, 2013 | Oct. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 31, 2013 | Oct. 07, 2013 | Dec. 31, 2013 | Oct. 31, 2013 | Dec. 31, 2012 | Jul. 31, 2012 | Jul. 31, 2012 | Dec. 31, 2012 | Aug. 31, 2008 | Dec. 31, 2013 | Dec. 31, 2012 | |||||||
Warrant [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | Bridge Loan [Member] | Bridge Loan [Member] | Bridge Loan [Member] | Bridge Loan [Member] | Bridge Loan [Member] | Bridge Loan [Member] | Bridge Loan [Member] | Mortgage Payable To First Niagara [Member] | Mortgage Payable To First Niagara [Member] | Mortgage Payable To First Niagara [Member] | Mortgage Payable To First Niagara [Member] | Mortgage Payable to Second Niagara [Member] | Mortgage Payable to Second Niagara [Member] | Capital Lease Payable To Ricoh [Member] | Capital Lease Payable To Ricoh [Member] | Capital Lease Payable To Ricoh [Member] | Capital Lease Payable To Ricoh [Member] | Capital Lease Payable To Marlin [Member] | Capital Lease Payable To Marlin [Member] | Capital Lease Payable To Marlin [Member] | Debenture Financing [Member] | Debenture Financing [Member] | Debenture Financing [Member] | Debenture Financing [Member] | Debenture Financing [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Series Debentures [Member] | Bridge Loan With Cantone Asset Management, Llc [Member] | Bridge Loan With Cantone Asset Management, Llc [Member] | Bridge Loan With Cantone Asset Management, Llc [Member] | Thirty Seven Debentures Holders [Member] | Five Debentures Holders [Member] | Five Debentures Holders [Member] | Cantone Series One Four Years warrant [Member] | Cantone Series One Four Years warrant [Member] | Cantone Series One Four Years warrant [Member] | |||||||||||||||
Restricted Stock [Member] | New Bridge Loan Agreement 2013 [Member] | New Bridge Loan Agreement 2013 [Member] | New Bridge Loan Agreement 2013 [Member] | New Bridge Loan Agreement 2013 [Member] | Existing Bridge Loan Agreement [Member] | New Placement Agreement 2013 [Member] | New Placement Agreement 2013 [Member] | Agreement with Thirty Holders [Member] | Agreement with One Holder [Member] | Agreement with Twenty Seven Holders [Member] | Agreement with Twenty Seven Holders [Member] | Agreement with Twenty Seven Holders [Member] | Agreement with Twenty Seven Holders [Member] | Agreement with Twenty Seven Holders [Member] | Agreement with Twenty Seven Holders [Member] | Agreement with Twenty Seven Holders [Member] | Agreement with Three Holders [Member] | Agreement with Three Holders [Member] | New Placement Agreement 2013 [Member] | New Placement Agreement 2013 [Member] | New Placement Agreement 2013 [Member] | New Placement Agreement 2013 [Member] | New Placement Agreement 2013 [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||
Warrant [Member] | Warrant [Member] | Restricted Stock [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Instrument [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Debt Instrument, Periodic Payment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $14,000 | $14,000 | [1] | ' | ' | ' | ' | ' | ' | ' | ' | ' | $147 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||
Debt Instrument, Interest Rate During Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8.25% | 9.25% | [1] | ' | ' | 8.25% | 9.25% | ' | 14.11% | ' | ' | 14.46% | 14.46% | ' | ' | 15.00% | 10.00% | 15.00% | [2] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15.00% | [3] | ' | ' | ' | ' | ' | ' | ' | ' | |||
Debt Instrument, Maturity Date | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1-Mar-14 | [1] | 1-Mar-13 | ' | ' | ' | ' | ' | ' | ' | ' | 1-Sep-13 | ' | ' | ' | ' | 1-Aug-14 | [2] | ' | 1-Aug-12 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1-Aug-14 | [3] | ' | ' | ' | ' | ' | ' | ' | ' | |||
Debt Issuance Cost | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Debt Instrument, Annual Principal Payment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,000 | ' | 25,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Amortization Of Debt Issuance Costs | ' | ' | ' | ' | ' | 267,000 | 47,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 60,000 | 21,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25,000 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Debt Instrument, Convertible, Remaining Discount Amortization Period | ' | '6 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Long-term Debt, Gross | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 815,000 | 452,000 | 608,000 | ' | ' | 14,437 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 795,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Interest Expense, Debt | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 48,000 | 56,000 | ' | ' | 14,115 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 122,000 | 93,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Payments to Acquire Equipment on Lease | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 17,000 | ' | ' | 4,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Operating Leases, Future Minimum Payments Due, Next Twelve Months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Proceeds from Issuance of Debt | ' | ' | 631,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 750,000 | ' | ' | 131,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Placement Agent Fees | ' | ' | 54,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 39,750 | ' | ' | ' | ' | 39,750 | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Legal and Accounting Fees | ' | ' | 63,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,000 | ' | ' | ' | ' | ' | ' | 4,000 | ' | ||||||
State Filing Fees | ' | ' | 2,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | ' | ' | 44,550 | ' | ' | ' | ' | ' | 44,550 | 30,450 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 30,450 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 543,500 | ' | ' | ' | ' | ' | 115,000 | ' | ' | 75,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | ' | ' | $0.40 | $0.40 | $0.37 | $0.14 | ' | ' | $0.40 | $0.37 | ' | ' | ' | ' | $250,000 | ' | $153,486 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.37 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.14 | ' | ' | ' | ' | ' | ' | ' | ' | $0.14 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Payments Of Debt Issuance Costs | ' | ' | ' | ' | ' | 161,000 | 50,000 | ' | ' | ' | ' | ' | ' | 50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Debt Issuance Agent Fee and Expenses | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 52,500 | ' | ' | ||||||
Placement Agent Fee Percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 7.00% | ' | ' | ||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12,000 | ' | ||||||
Amortization Of Debt Issuance Cost | ' | ' | ' | ' | ' | 286,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 29,000 | 21,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 19,000 | ||||||
Allocated Share-based Compensation Expense, Total | ' | ' | ' | ' | ' | 32,000 | 12,000 | ' | ' | ' | 0 | 2,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,000 | 2,000 | ||||||
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum | ' | ' | ' | ' | ' | 10.00% | 10.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum | ' | ' | ' | ' | ' | 15.00% | 15.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Percentage Of Cash Fee Of Gross Amount Of Existing Debentures | ' | ' | ' | ' | ' | 5.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Placement Agent Services Compensation | ' | ' | ' | ' | ' | 37,500 | 39,750 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Warrants Issued Amended Purchase Price Per Share | ' | ' | ' | ' | ' | $0.17 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Warrants Issued Amended Term | ' | ' | ' | ' | ' | '3 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Non Accountable Expense Allowance Percentage On Gross Amount Of Debentures | ' | ' | ' | ' | ' | 1.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Reimbursed In Legal Fees | ' | ' | ' | ' | ' | 5,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Amortization Period Of Debentures | ' | ' | ' | ' | ' | '1 year | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '1 year | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Bridge Loan | ' | ' | ' | ' | ' | ' | ' | 150,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | 150,000 | ' | ' | ' | ' | ' | ' | ' | ||||||
Payments To Debentures Holders | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 105,000 | ' | ' | ' | ' | ||||||
Percentage Of Simple Interest In Advance Of Bridge Loan | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15.00% | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Proceeds From Bridge Loan | ' | ' | ' | ' | ' | 6,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Restricted Stock Award Issued Price Per Share | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.17 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 88,235 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 225,000 | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Long-term Debt, Total | ' | ' | ' | ' | ' | 1,286,000 | 1,404,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 452,000 | [1] | 608,000 | [1] | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 1,000 | ' | 645,000 | [2] | ' | 634,000 | [2] | 105,000 | 634,000 | ' | 750,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | [3] | ' | 150,000 | [3] | 645,000 | ' | ' | ' | ' | ' |
Debt Instrument, Interest Rate, Stated Percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15.00% | ' | ' | ' | ' | ' | ||||||
Proceeds from Short-term Debt, Total | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,000 | ' | ' | ' | ||||||
Interest and Debt Expense, Total | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 27,000 | 26,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Long Term Debt Accrued Interest Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15.00% | ' | 15.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Unamortized Debt Issuance Expense | ' | ' | ' | ' | ' | 80,000 | 29,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Opting To Purchase Description | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'the Company notified RICOH that it was opting to purchase the copier for $1.00 as provided in the Company’s lease. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Leasing Term | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | ' | '3 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Non Accountable Expense Allowance | ' | ' | ' | ' | ' | 7,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Debt Instrument, Unamortized Discount (Premium), Net, Total | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 60,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Percentage Of Cash Fee Of Gross Amount Of Existing Debentures | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '2 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Legal Fees | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | ' | ' | ' | ' | ' | ' | ' | 77.00% | 0.00% | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 2.65% | ' | ' | ' | ' | ' | ' | ' | 4.60% | 4.70% | ' | ' | ' | ' | 2.65% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2.65% | ' | ' | ' | ' | ' | ' | ' | ' | 2.65% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term | '1 year | ' | ' | ' | ' | ' | ' | ' | '4 years | '4 years | ' | ' | ' | ' | ' | ' | ' | ' | '1 year | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '1 year | ' | ' | ' | ' | ' | ' | ' | ' | '1 year | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Warrants and Rights Outstanding | ' | ' | ' | ' | ' | 3,303,000 | 375,000 | ' | ' | ' | ' | ' | ' | ' | ' | 35,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 44,000 | 44,000 | 76,000 | ' | ' | ' | ' | ' | ' | 10,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Percentage of Warrants Expenses Recognized During Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Warrants Issuance Recognized During Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 35,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 32,000 | ' | ' | ' | ' | ' | ' | ' | 10,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Proceeds from Issuance of Long-term Debt, Total | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Repayment of Long Term Debt Through Issue of Restricted Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 150,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number, Beginning Balance | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 225,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Interest to be Paid Through Share Based Compensation Arrangements | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Percentage of Share Based Compensation Award Exercisable on Date of Grant | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Long-term Debt, Current Maturities, Total | ' | ' | ' | ' | ' | 1,226,000 | 1,404,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 634,500 | ' | ' | ' | 543,500 | ' | ' | ' | ' | ' | 91,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Repayments of Long-term Debt, Total | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Long Term Debt, Extension Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '1 year | ' | ' | ' | ' | ' | ' | '1 year | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Interest Expense, Long-term Debt, Total | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 122,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Interest Payable | ' | ' | ' | ' | ' | 35,000 | 29,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 27,000 | 26,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Net Proceeds from Issuance of Long Term Debt | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 6,250 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Debt Instrument, Repurchase Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Debt Instrument, Face Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $635,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | ' | ' | ' | ' | ' | ' | ' | ' | 46.10% | 46.00% | ' | ' | ' | ' | 73.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 73.00% | ' | ' | ' | ' | ' | ' | 73.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ||||||
[1] | The mortgage through First Niagara was refinanced and extended on March 8, 2013. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[2] | The original debt with the Series A Debenture Holders was $750,000, with an interest rate of 10% per annum. It was payable semi-annually in August and February of each year with the first payment due February 1, 2009 and a maturity date of August 1, 2012. In July 2012, the Series A Debentures were amended and extended; under the amendment and extension the interest rate from August 1, 2012 through December 31, 2012 was increased to 15% per annum (the interest rate from January 1, 2012 through July 31, 2012 remained at 10%), and the maturity date was extended to August 1, 2013, and $105,000 of Series A Debentures were repaid with a portion of loan proceeds from Cantone Asset Management LLC; lowering the principal of the Series A Debenture to $645,000. The Series A Debentures were amended and extended in October 2013, and the terms noted in the table above are the revised terms of the Series A Debentures. $10,000 in Series A Debentures was repaid under the extension, lowering the principal to $635,000 at December 31, 2013. Even after the amendment and extension, the Series A Debentures remained classified as a current liability given their maturity date of August 1, 2014. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
[3] | In October 2013, the Company increased our Bridge Loan with Cantone Asset Management LLC from $150,000 to $200,000. The additional $50,000 was used to pay placement agent fees of $39,750 and Cantone Research Incbs legal fees of $4,000. The remaining proceeds (approx $6,000) were remitted to the Company and used toward the repayment of the $10,000 in non-extending Series A Debentures. |
LINES_OF_CREDIT_Details_Textua
LINES OF CREDIT (Details Textual) (USD $) | 1 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | ||||||||||||||||
Aug. 31, 2008 | Mar. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Feb. 23, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Jan. 16, 2013 | Dec. 31, 2013 | Jan. 16, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Jan. 16, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2013 | Jan. 16, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Jul. 31, 2009 | |
Mortgage Payable to First Niagara [Member] | Mortgage Payable to First Niagara [Member] | Mortgage Payable to First Niagara [Member] | Mortgage Payable to First Niagara [Member] | Series A Debentures [Member] | Series A Debentures [Member] | Series A Debentures [Member] | Series A Debentures [Member] | Bridge Loan with Cantone Asset Management, Llc [Member] | Monarch Capital Group Llc [Member] | Monarch Capital Group Llc [Member] | Imperium Warrants [Member] | Imperium Line of Credit [Member] | Imperium Line of Credit [Member] | Imperium Line of Credit [Member] | Imperium Supplemental Advance [Member] | Medallion Line of Credit [Member] | Medallion Line of Credit [Member] | Medallion Line of Credit [Member] | Medallion Line of Credit [Member] | Rosenthal Line of Credit [Member] | Rosenthal Line of Credit [Member] | Rosenthal Line of Credit [Member] | |||||
New Placement Agreement 2013 [Member] | New Placement Agreement 2013 [Member] | ||||||||||||||||||||||||||
Maximum Funding Amounts Subject To Discretionary Borrowing | ' | ' | 'The Maximum Funding Amount is subject to a discretionary borrowing base comprised of: 85% of eligible accounts receivables (excluding, without limitation, receivables remaining unpaid for more than 90 days from invoice date or 60 days from due date, contra receivables, and affiliated receivables), up to the lesser of 60% of eligible finished goods inventory at cost or 75% of appraised net orderly liquidation value of inventory, and a receivable dilution rate of less than 5% (the Borrowing Base). | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Maximum Borrowing Capacity | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1,000,000 | ' | $1,500,000 | ' | $0 | ' | ' | ' | ' | ' | $1,500,000 |
Line of Credit Facility, Closing Fee | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,000 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Class of Warrant or Right Term of Warrants or Rights | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '5 years | ' | '7 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 60,000 | 60,000 | 2,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Class of Warrant or Right, Exercise Price of Warrants or Rights | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.18 | ' | $0.18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Termination Fee | ' | ' | 25,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 25,000 | ' | ' | ' | ' |
Finders Fee as Percentage of Financing Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Interest Rate During Period | ' | ' | 10.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line Of Credit Facility Monthly Collateral Fees Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Success Fee Terms | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'A success fee of $175,000 (Success Fee) is due and payable if Imperium terminates due to an event of default, or if the Company terminates and pre-pays all amounts due to Imperium prior to the stated expiration date of January 16, 2016, however, the Success Fee is not due and payable if Imperium has exercised all its rights under the Imperium Warrant and sells all of the common shares underlying the Imperium Warrant on or before January 16, 2016 and if on the date that Imperium completes such sale(s), the price per share of the Companys common shares is at least $0.70 per common share. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Interest Rate Supplemental Advance in Cash, Percentage | ' | ' | 8.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Payment in Kind Interest, Percentage | ' | ' | 2.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage Increase in Interest on Default of Covenant Terms | ' | 4.00% | 4.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Eligible Accounts Receivable, Advance Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 85.00% | ' | ' | ' | ' | ' | ' |
Eligible Inventory Percentage, Advance Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 60.00% | ' | ' | ' | ' | ' | ' |
Maximum Inventory Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 150,000 | ' | ' | ' | ' | ' | ' |
Proceeds from Lines of Credit | ' | ' | 10,142,000 | 10,185,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 566,000 | ' | ' | ' | ' | ' | ' |
Facility Fee Percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.00% | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Interest Rate Description | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'Under the Loan Agreement, interest on outstanding borrowings was payable monthly and was charged at an annual rate equal to 4% above the Wall Street Journal Prime rate as published from time to time. | ' | ' | ' | ' | ' | ' |
Payment of Audit Fees Per Day | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 950 | ' | ' | ' | ' | ' | ' |
Non Refundable Field Exam and Due Diligence Costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,000 | ' | ' | ' | ' | ' | ' |
Line of Credit Facility Costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 435,000 | ' | ' | ' | 0 | 20,000 | ' | ' | 41,000 | 7,000 | ' |
Line of Credit Facility, Periodic Payment, Interest | ' | ' | 8,000 | 42,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 122,000 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Amount Outstanding | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 980,000 | 0 | ' | 200,000 | ' | 321,000 | ' | 0 | 0 | 0 | ' |
Line of Credit Facility, Additional Borrowing Capacity | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,000 | ' | ' | 0 | ' | ' | ' | ' | ' | ' | ' |
Line of credit | ' | ' | 987,000 | 321,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,180,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Administrative Fee Paid Per Month | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,500 |
Line of Credit Facility, Administrative Fee Paid | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15,000 |
Line of Credit Facility, Monthly Periodic Payment Interest | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,000 |
Amortization of Financing Costs | ' | ' | 267,000 | 47,000 | 1,000 | ' | ' | ' | 60,000 | 21,000 | 25,000 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' |
Interest Expense, Debt | ' | ' | ' | ' | ' | 48,000 | 56,000 | ' | 122,000 | 93,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,000 | ' | ' | 0 | 19,000 | ' |
Legal and Accounting Fees | 63,000 | ' | ' | ' | ' | ' | 2,000 | ' | ' | ' | ' | ' | 4,000 | ' | ' | ' | 39,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Amortization of Debt Issuance Cost | ' | ' | 286,000 | ' | ' | ' | ' | ' | 29,000 | 21,000 | ' | ' | ' | ' | ' | ' | 257,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Current Borrowing Capacity | ' | ' | 12,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 2,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Instrument Deferred Finance Costs | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Issuance Cost | ' | ' | ' | ' | ' | ' | ' | 2,000 | ' | ' | ' | ' | ' | ' | ' | ' | 435,000 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Covenant Terms | ' | ' | 'Net Borrowing Availability of not less than $100,000 (Net Borrowing Availability is defined as borrowing availability less the amounts due under the Imperium Line of Credit). There are also certain minimum EBITDA (Earnings Before Interest, Taxes Depreciation and Amortization) requirements. More specifically, the Company must have EBITDA of not less than (a) $25,000 for the Fiscal Quarter ended on or about March 31, 2013, (b) $100,000 for the Fiscal Quarter ended on or about June 30, 2013, (c) $200,000 for the Fiscal Quarter ending on or about September 30, 2013, and (d) $300,000 for the Fiscal Quarter ending on or about December 31, 2013 and for each of the Fiscal Quarters thereafter. | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Line of Credit Facility, Borrowing Capacity, Description | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 'Imperium notified the Company that it was reducing the Maximum Funding Amount on the Imperium Line of Credit from $1,500,000 to $1,100,000 (however, the Company must continue to maintain minimum Net Borrowing Availability of $100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Instrument, Unamortized Discount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $97,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
INCOME_TAXES_Details
INCOME TAXES (Details) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Income Tax Disclosure [Line Items] | ' | ' |
Tax expense at federal statutory rate | 34.00% | 34.00% |
State tax expense, net of federal tax effect | 5.00% | 5.00% |
Permanent timing differences | -10.00% | -4.00% |
Deferred income tax asset valuation allowance | -29.00% | -35.00% |
Effective income tax rate | 0.00% | 0.00% |
INCOME_TAXES_Details_1
INCOME TAXES (Details 1) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Deferred Income Tax Assets [Line Items] | ' | ' |
Inventory | $15,000 | $18,000 |
Inventory allowance | 156,000 | 102,000 |
Allowance for doubtful accounts | 23,000 | 23,000 |
Accrued compensation | 27,000 | 27,000 |
Net operating loss carry forward expired | 0 | -197,000 |
Net operating loss carry-forward | 5,026,000 | 5,013,000 |
Total gross deferred income tax assets | 5,247,000 | 4,986,000 |
Less deferred income tax assets valuation allowance | -5,247,000 | -4,986,000 |
Net deferred income tax assets | $0 | $0 |
INCOME_TAXES_Details_Textual
INCOME TAXES (Details Textual) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Income Tax [Line Items] | ' | ' |
Deferred Tax Assets, Valuation Allowance | $5,247,000 | $4,986,000 |
Valuation Allowance, Deferred Tax Asset, Change in Amount | 261,000 | 213,000 |
Operating Loss Carryforwards Expiration Period | 'expire in 2011 and continue to expire through 2033 | ' |
Operating Loss Carryforwards | $12,888,000 | ' |
OTHER_INCOME_EXPENSE_Details_T
OTHER INCOME / EXPENSE (Details Textual) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Other Income Expense [Line Items] | ' | ' |
Grant Convertible Into Loans Percentage | '90% of the grant amount in 2003 to 0% in 2012. | ' |
Employees In Kinderhook Facility | 45 | 47 |
Columbia Economic Development Corporation [Member] | ' | ' |
Other Income Expense [Line Items] | ' | ' |
Revenue from Grants | ' | 10,000 |
Gain (Loss) on Disposition of Property Plant Equipment, Total | 100,000 | 1,000 |
STOCKHOLDERS_EQUITY_Details
STOCKHOLDERS' EQUITY (Details) (USD $) | 1 Months Ended | 12 Months Ended | |
Apr. 20, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | |
Share Based Compensation Stock Options Activity [Line Items] | ' | ' | ' |
Shares,Options outstanding at beginning of year | ' | 2,939,000 | 2,699,000 |
Shares,Granted | ' | 902,000 | 750,000 |
Shares,Exercised | ' | 0 | 0 |
Shares,Cancelled/expired | ' | -525,000 | -510,000 |
Shares,Options outstanding at end of year | ' | 3,316,000 | 2,939,000 |
Shares,Options exercisable at end of year | ' | 2,747,000 | 2,189,000 |
Weighted Average Exercise Price,Options outstanding at beginning of year | ' | $0.69 | $0.76 |
Weighted Average Exercise Price,Granted | $0.18 | $0.13 | $0.18 |
Weighted Average Exercise Price,Cancelled/expired | ' | $0.64 | $1.06 |
Weighted Average Exercise Price,Options outstanding at end of year | ' | $0.44 | $0.69 |
Weighted Average Exercise Price,Options exercisable at end of year | ' | $0.49 | $0.69 |
STOCKHOLDERS_EQUITY_Details_1
STOCKHOLDERS' EQUITY (Details 1) (USD $) | 12 Months Ended |
Dec. 31, 2013 | |
Stock Option Plans By Exercise Price Range [Line Items] | ' |
Options Outstanding, Shares | 3,316,000 |
Options Outstanding, Weighted Average Exercise Price | $0.44 |
Options Outstanding, Weighted Average Remaining Life in Years | '5 years 7 months 24 days |
Options Exercisable, Shares | 2,747,000 |
Options Exercisable, Weighted Average Exercise Price | $0.49 |
Range of Exercise Price 0.07 - 0.20 [Member] | ' |
Stock Option Plans By Exercise Price Range [Line Items] | ' |
Range of Exercise Price, Minimum | $0.07 |
Range of Exercise Price, Maximum | $0.20 |
Options Outstanding, Shares | 2,220,000 |
Options Outstanding, Weighted Average Exercise Price | $0.16 |
Options Outstanding, Weighted Average Remaining Life in Years | '7 years 8 months 23 days |
Options Exercisable, Shares | 1,753,000 |
Options Exercisable, Weighted Average Exercise Price | $0.16 |
Range of Exercise Price 0.26 - 0.85 [Member] | ' |
Stock Option Plans By Exercise Price Range [Line Items] | ' |
Range of Exercise Price, Minimum | $0.26 |
Range of Exercise Price, Maximum | $0.85 |
Options Outstanding, Shares | 137,000 |
Options Outstanding, Weighted Average Exercise Price | $0.41 |
Options Outstanding, Weighted Average Remaining Life in Years | '7 years 1 month 28 days |
Options Exercisable, Shares | 35,000 |
Options Exercisable, Weighted Average Exercise Price | $0.85 |
Range of Exercise Price 0.86 - 1.09 [Member] | ' |
Stock Option Plans By Exercise Price Range [Line Items] | ' |
Range of Exercise Price, Minimum | $0.86 |
Range of Exercise Price, Maximum | $1.09 |
Options Outstanding, Shares | 874,000 |
Options Outstanding, Weighted Average Exercise Price | $1.05 |
Options Outstanding, Weighted Average Remaining Life in Years | '8 months 1 day |
Options Exercisable, Shares | 874,000 |
Options Exercisable, Weighted Average Exercise Price | $1.05 |
Range of Exercise Price 1.14 - 1.74 [Member] | ' |
Stock Option Plans By Exercise Price Range [Line Items] | ' |
Range of Exercise Price, Minimum | $1.14 |
Range of Exercise Price, Maximum | $1.74 |
Options Outstanding, Shares | 85,000 |
Options Outstanding, Weighted Average Exercise Price | $1.52 |
Options Outstanding, Weighted Average Remaining Life in Years | '1 month 17 days |
Options Exercisable, Shares | 85,000 |
Options Exercisable, Weighted Average Exercise Price | $1.52 |
STOCKHOLDERS_EQUITY_Details_Te
STOCKHOLDERS' EQUITY (Details Textual) (USD $) | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 7 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 9 Months Ended | 12 Months Ended | 0 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Oct. 07, 2013 | Apr. 20, 2012 | Aug. 31, 2008 | Aug. 04, 2008 | Jul. 17, 2008 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 30, 2012 | Dec. 31, 2011 | Oct. 31, 2013 | Dec. 31, 2012 | Sep. 20, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 20, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 20, 2013 | Jun. 20, 2013 | Jun. 25, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 25, 2013 | Jun. 25, 2013 | Jun. 25, 2013 | Apr. 15, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Apr. 15, 2013 | Apr. 15, 2013 | Apr. 26, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Apr. 26, 2013 | Apr. 26, 2013 | Dec. 31, 2013 | Jul. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 07, 2013 | Oct. 07, 2013 | Oct. 07, 2013 | Oct. 07, 2013 | Jul. 31, 2012 | Dec. 31, 2012 | Aug. 04, 2008 | Jul. 17, 2008 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 31, 2013 | Oct. 07, 2013 | Oct. 07, 2013 | Sep. 20, 2012 | Sep. 20, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2009 | Dec. 31, 2009 | Feb. 21, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Apr. 20, 2012 | Apr. 20, 2012 | Apr. 20, 2012 | Apr. 20, 2012 | Apr. 20, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Jan. 16, 2013 | Sep. 30, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Mar. 31, 2013 | Jan. 16, 2013 | Jan. 16, 2013 | Jan. 16, 2013 | Jan. 16, 2013 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Apr. 20, 2012 | Aug. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Apr. 20, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Apr. 20, 2012 | Apr. 20, 2012 | Apr. 20, 2012 | Apr. 20, 2012 | Dec. 31, 2013 | Jan. 16, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Jan. 16, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Oct. 07, 2013 | Dec. 31, 2013 | Oct. 07, 2013 | |
Bridge Loan [Member] | September 2012 Employee Stock Options [Member] | Two Non Executive Employees [Member] | Two Non Executive Employees [Member] | Fiscal 2000 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2013 Non Statutory Stock Option Plan [Member] | Series A Debentures [Member] | Series A Debentures [Member] | Series A Debentures [Member] | Series A Debentures [Member] | Series A Debentures [Member] | Series A Debentures [Member] | Series A Debentures [Member] | Cantone Asset Management, Llc Warrants [Member] | Cantone Asset Management, Llc Warrants [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | Warrant [Member] | ABMC Common Stock [Member] | September 20, 2014 [Member] | September 20, 2015 [Member] | Rosenthal Line Of Credit Stock Options [Member] | Rosenthal Line Of Credit Stock Options [Member] | Rosenthal Line Of Credit Stock Options [Member] | Rosenthal Line Of Credit Stock Options [Member] | Stock Options February 2013 [Member] | Stock Options February 2013 [Member] | Stock Options February 2013 [Member] | Medallion Line of Credit Stock Options [Member] | Medallion Line of Credit Stock Options [Member] | Medallion Line of Credit Stock Options [Member] | Medallion Line of Credit Stock Options [Member] | Medallion Line of Credit Stock Options [Member] | Stock Option Plan 2000 [Member] | Stock Option Plan 2011 [Member] | Cipkowski Imperium Stock Option [Member] | Cipkowski Imperium Stock Option [Member] | Cipkowski Imperium Stock Option [Member] | Cipkowski Imperium Stock Option [Member] | Cipkowski Imperium Stock Option [Member] | Cipkowski Imperium Stock Option [Member] | Cipkowski Imperium Stock Option [Member] | Cipkowski Imperium Stock Option [Member] | Cipkowski Imperium Stock Option [Member] | Cipkowski Medallion Stock Option [Member] | Cipkowski Medallion Stock Option [Member] | Cipkowski Medallion Stock Option [Member] | Cipkowski Medallion Stock Option [Member] | Urquhart Medallion Stock Option [Member] | Urquhart Medallion Stock Option [Member] | Urquhart Medallion Stock Option [Member] | Jaskiewicz Medallion Stock Option [Member] | Jaskiewicz Medallion Stock Option [Member] | Jaskiewicz Medallion Stock Option [Member] | Jaskiewicz Medallion Stock Option [Member] | Jaskiewicz Medallion Stock Option [Member] | Jaskiewicz Medallion Stock Option [Member] | Jaskiewicz Medallion Stock Option [Member] | Urquhart Stock Option [Member] | Imperium Warrants [Member] | Imperium Warrants [Member] | Imperium Warrants [Member] | Monarch Warrant [Member] | Monarch Warrant [Member] | Monarch Warrant [Member] | Cantone warrant [Member] | Cantone warrant [Member] | CAM warrant [Member] | ||||||||||
New Bridge Loan Agreement 2013 [Member] | September 2012 Employee Stock Options [Member] | September 2012 Employee Stock Options [Member] | Science Advisory Board [Member] | Science Advisory Board [Member] | Science Advisory Board [Member] | Science Advisory Board [Member] | Science Advisory Board [Member] | Executive Vice President [Member] | Executive Vice President [Member] | Executive Vice President [Member] | Executive Vice President [Member] | Executive Vice President [Member] | Executive Vice President [Member] | Another Science Advisory Board [Member] | Another Science Advisory Board [Member] | Another Science Advisory Board [Member] | Another Science Advisory Board [Member] | Another Science Advisory Board [Member] | Consultant [Member] | Consultant [Member] | Consultant [Member] | Consultant [Member] | Consultant [Member] | Agreement with Thirty Holders [Member] | Agreement with One Holder [Member] | Agreement with Twenty Seven Holders [Member] | Agreement with Three Holders [Member] | Bridge Loan [Member] | Bridge Loan [Member] | Two Non Executive Employees [Member] | Two Non Executive Employees [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | Fiscal 2013 Non Statutory Stock Option Plan [Member] | Fiscal 2013 Non Statutory Stock Option Plan [Member] | Fiscal 2013 Non Statutory Stock Option Plan [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | April 20, 2014 [Member] | April 20, 2013 [Member] | April 20, 2015 [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | January 16, 2014 [Member] | January 16, 2015 [Member] | January 16, 2016 [Member] | Medallion Line of Credit Stock Options [Member] | Fiscal 2001 Non Statutory Stock Option Plan [Member] | April 20, 2014 [Member] | April 20, 2013 [Member] | April 20, 2015 [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Restricted Stock [Member] | June 20 2014 [Member] | June 20 2015 [Member] | June 25 2014 [Member] | June 25 2015 [Member] | June 20 2016 [Member] | April 15 2014 [Member] | April 15 2015 [Member] | April 26 2014 [Member] | April 26, 2015 [Member] | New Bridge Loan Agreement 2013 [Member] | New Bridge Loan Agreement 2013 [Member] | September 2012 Employee Stock Options [Member] | September 2012 Employee Stock Options [Member] | One Executive Officer Thirteen Non Executive Employees And One Consultant [Member] | One Executive Officer Thirteen Non Executive Employees And One Consultant [Member] | One Executive Officer Thirteen Non Executive Employees And One Consultant [Member] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders Equity [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | ' | ' | ' | ' | ' | 902,000 | 750,000 | ' | ' | ' | ' | 100,000 | ' | ' | 902,000 | 750,000 | 25,000 | ' | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | 25,000 | ' | ' | ' | ' | 50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | 102,000 | ' | ' | ' | 250,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 500,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 150,000 | ' | ' | ' | ' | 2,000,000 | ' | ' | 60,000 | ' | ' | 75,000 | ' | 250,000 |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | ' | $0.18 | ' | ' | ' | $0.13 | $0.18 | ' | ' | ' | ' | $0.18 | ' | ' | ' | ' | $0.14 | ' | ' | ' | ' | $0.14 | ' | ' | ' | ' | ' | $0.16 | ' | ' | ' | ' | $0.18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.20 | ' | $0.26 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.15 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.18 | ' | ' | ' | ' | ' | ' | ' | $0.18 | ' | ' | $0.18 | ' | ' | $0.14 | ' | $0.14 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12,500 | 12,500 | ' | ' | ' | 66,000 | 66,000 | 68,000 | ' | ' | ' | 12,500 | 12,500 | ' | ' | ' | 25,000 | 25,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 33,000 | 34,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 82,500 | 82,500 | 85,000 | ' | ' | ' | ' | ' | ' | ' | ' | 165,000 | 165,000 | 170,000 | ' | ' | ' | ' | 82,500 | ' | ' | ' | ' | ' | ' | 49,500 | 49,500 | 51,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $18,000 | ' | ' | ' | ' | $4,000 | ' | ' | ' | ' | $28,000 | ' | ' | ' | ' | ' | $4,000 | ' | ' | ' | ' | $9,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.16 | ' | $27,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | $73,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $290,000 | ' | ' | $9,000 | ' | ' | $10,000 | ' | $35,000 |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | ' | 0.00% | 77.00% | 0.00% | ' | ' | 0.00% | ' | ' | ' | ' | ' | ' | 0.00% | ' | 0.00% | ' | ' | 0.00% | ' | ' | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.00% | ' | ' | ' | ' | ' | ' | ' | 0.00% | ' | ' | 0.00% | ' | ' | 0.00% | ' | 0.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 2.65% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.80% | ' | ' | ' | ' | 2.41% | ' | ' | ' | ' | 2.60% | ' | ' | ' | ' | ' | 1.72% | ' | ' | ' | ' | 1.70% | ' | ' | ' | ' | ' | ' | ' | 1.51% | ' | ' | ' | ' | ' | 1.56% | 4.60% | 4.70% | ' | ' | 2.65% | ' | ' | ' | ' | ' | ' | 4.34% | ' | 1.99% | ' | ' | 1.99% | ' | ' | ' | ' | ' | ' | 1.84% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1.99% | ' | ' | ' | ' | ' | ' | ' | 1.84% | ' | ' | 1.84% | ' | ' | 2.65% | ' | 2.65% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 85.00% | ' | ' | ' | ' | 74.00% | ' | ' | ' | ' | 74.00% | ' | ' | ' | ' | ' | 76.00% | ' | ' | ' | ' | 76.00% | ' | ' | ' | ' | ' | ' | ' | 77.00% | ' | ' | ' | ' | ' | 77.00% | 46.10% | 46.00% | ' | ' | 73.00% | ' | 73.00% | ' | ' | ' | ' | 69.00% | ' | 82.00% | ' | ' | 88.00% | ' | ' | ' | ' | ' | ' | 82.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 88.00% | ' | ' | ' | ' | ' | ' | ' | 82.00% | ' | ' | 82.00% | ' | ' | 73.00% | ' | 73.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term | '1 year | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | ' | '3 years | ' | ' | ' | ' | ' | ' | '3 years | ' | '4 years | '4 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' | '10 years | ' | ' | '10 years | ' | ' | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '10 years | ' | ' | ' | ' | ' | ' | ' | '7 years | ' | ' | '5 years | ' | ' | '10 years | ' | '10 years |
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '36 months | ' | ' | ' | ' | '24 months | ' | ' | ' | ' | '36 months | ' | ' | ' | ' | ' | '24 months | ' | ' | ' | ' | '24 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '3 years | ' | '12 months | ' | ' | '36 months | ' | ' | ' | ' | ' | ' | '36 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '36 months | ' | ' | '36 months | ' | ' | ' | ' | ' | ' | ' | '7 years | ' | ' | '5 years | ' | ' | '3 years | ' | '3 years |
Amortized Share Based Payment Expense | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 97,000 | 0 | ' | 3,000 | 0 | ' | 10,000 | 35,000 |
Allocated Share Based Compensation Expense | ' | ' | ' | ' | ' | 32,000 | 12,000 | ' | ' | ' | 2,000 | ' | 6,000 | ' | ' | ' | ' | 1,000 | 0 | ' | ' | ' | ' | 0 | ' | ' | ' | ' | 2,000 | 0 | ' | ' | ' | 3,000 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | 2,000 | ' | ' | ' | ' | ' | 0 | 13,000 | ' | ' | ' | 24,000 | 0 | ' | ' | ' | ' | ' | ' | ' | ' | 18,000 | 73,000 | 0 | ' | ' | ' | ' | ' | 23,000 | 34,000 | 11,000 | ' | 13,000 | ' | 11,000 | ' | 9,000 | 7,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | ' | ' | ' | ' | ' | 44,000 | ' | ' | ' | ' | ' | ' | 10,000 | ' | ' | ' | ' | 3,000 | ' | ' | ' | ' | 23,000 | ' | ' | ' | ' | ' | 2,000 | ' | ' | ' | ' | 6,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | ' | ' | 0 | ' | ' | ' | ' | 3,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0 | ' | 54,000 | ' | ' | ' | ' | 0 | 0 | ' | ' | ' | 0 | ' | 11,000 | ' | ' | ' | ' | ' | ' | ' | ' | 193,000 | ' | ' | 6,000 | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | ' | ' | ' | ' | ' | '7 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '17 months | ' | ' | ' | ' | '29 months | ' | ' | ' | ' | ' | '15 months | ' | ' | ' | ' | '15 months | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | '0 years | ' | ' | ' | ' | ' | ' | '0 years | ' | ' | ' | ' | '1 month | ' | ' | ' | ' | ' | ' | ' | ' | '36 months | ' | '0 months | ' | ' | ' | ' | ' | ' | ' | '0 months | ' | ' | ' | '0 months | ' | ' | '15 months | ' | ' | ' | ' | ' | '0 months | '24 years | ' | ' | '24 years | ' | ' | ' | '0 months | ' |
Stock Granted During Period, Value, Share-based Compensation, Gross | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 90,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 45,000 | ' | ' | ' | 27,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage of Stock Option Grant Exercisable | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100.00% | ' | ' | 100.00% | ' | ' | ' | ' | 100.00% |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | ' | ' | $0.40 | $0.40 | $0.37 | $0.14 | ' | ' | ' | $153,486 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.14 | ' | ' | ' | $0.40 | $0.37 | ' | ' | $250,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period | ' | ' | 44,550 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 44,550 | 30,450 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Fair Value Of Warrant | 76,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Purchase Of Shares By Granted Of Stock Options | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 50,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Shares,Cancelled/expired | ' | ' | ' | ' | ' | -525,000 | -510,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 167,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Related Party Note | ' | ' | ' | ' | ' | 124,000 | 124,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 124,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | ' | ' | ' | ' | ' | 3,316,000 | ' | ' | ' | ' | ' | ' | ' | 1,000,000 | 4,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 9,000 | 3,307,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,316,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | ' | ' | ' | ' | ' | 2,747,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 409,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 4,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | ' | ' | ' | ' | ' | 3,316,000 | 2,939,000 | ' | 2,699,000 | ' | ' | ' | ' | 9,000 | 3,307,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 3,316,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant In Period Intrinsic Value | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 78,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants and Rights Outstanding | ' | ' | ' | ' | ' | 3,303,000 | 375,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 35,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | ' | ' | ' | ' | ' | $0.13 | $0.18 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $12,000 | $12,000 | ' | ' | ' | ' | ' | $48,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price | ' | ' | ' | ' | ' | $0.49 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $0.17 | $0.16 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrant Expense In Future | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 12,000 | ' | ' | ' | ' | ' | 48,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Percentage Of Share Based Compensation | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 100.00% | ' | 100.00% |
Stock Issued During Period Shares Issued For Interest payment | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 300,000 |
Bridge Loan | ' | ' | ' | ' | ' | ' | ' | 150,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 |
Debt Instrument, Interest Rate, Effective Percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 15.00% |
Stock Issued During Period, Shares, Restricted Stock Award, Gross | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 153,486 |
Warrnts To Purchase Common Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 543,500 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Long-term Debt, Current Maturities, Total | ' | ' | ' | ' | ' | $1,226,000 | $1,404,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $634,500 | $10,500 | $543,500 | $91,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Number of Outstanding Options | ' | ' | ' | ' | ' | 3,316,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 8,000 | 3,307,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
COMMITMENTS_CONTINGENCIES_AND_2
COMMITMENTS, CONTINGENCIES AND OTHER MATTERS (Details) (USD $) | Dec. 31, 2013 |
Future Minimum Rental Payments For Operating Leases [Line Items] | ' |
2014 | $95,000 |
Operating Leases, Future Minimum Payments Due | $95,000 |
COMMITMENTS_CONTINGENCIES_AND_3
COMMITMENTS, CONTINGENCIES AND OTHER MATTERS (Details Textual) (USD $) | 1 Months Ended | 12 Months Ended | |
Mar. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | |
Operating Leases, Rent Expense | ' | $122,000 | $122,000 |
Officers Compensation | ' | 140,000 | ' |
Loss Contingency, Damages Paid, Value | 150,000 | ' | ' |
Stan Cipkowski, Ceo [Member] | ' | ' | ' |
Officers Compensation | ' | 206,000 | ' |
Office And Research And Development Or Production Facilities [Member] | ' | ' | ' |
Operating Leases, Future Minimum Payments Due, Next Twelve Months | ' | 90,000 | ' |
Office Support Equipment [Member] | ' | ' | ' |
Operating Leases, Future Minimum Payments Due, Next Twelve Months | ' | $5,000 | ' |
RELATED_PARTY_DISCLOSURES_Deta
RELATED PARTY DISCLOSURES (Details Textual) (USD $) | 1 Months Ended | 12 Months Ended | |||||
Apr. 20, 2012 | Jul. 01, 2011 | Jul. 01, 2010 | Jul. 01, 2009 | Dec. 31, 2013 | Dec. 31, 2012 | Jun. 29, 2009 | |
Related Party Transaction [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross | ' | ' | ' | ' | 902,000 | 750,000 | ' |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $0.18 | ' | ' | ' | $0.13 | $0.18 | ' |
Edmund M Jaskiewicz [Member] | ' | ' | ' | ' | ' | ' | ' |
Related Party Transaction [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Related Party Transaction, Amounts of Transaction | ' | ' | ' | ' | $5,000 | $10,000 | ' |
Accounts Payable, Related Parties, Current | ' | ' | ' | ' | 32,000 | ' | ' |
Long-term Line of Credit | ' | ' | ' | ' | ' | ' | 124,000 |
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross | 150,000 | 50,000 | 50,000 | 50,000 | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total | ' | 150,000 | ' | ' | ' | ' | ' |
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $0.18 | $0.13 | $0.07 | $0.20 | ' | ' | ' |
Stock Options Grant Vested Current year | ' | ' | ' | ' | 49,500 | ' | ' |
Stock Options Grant Vested Secound Year | ' | ' | ' | ' | 49,500 | ' | ' |
Stock Options Grant Vested Third Year | ' | ' | ' | ' | 51,000 | ' | ' |
Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Period | '36 years | ' | ' | ' | ' | ' | ' |
Alec Cipkowski [Member] | ' | ' | ' | ' | ' | ' | ' |
Related Party Transaction [Line Items] | ' | ' | ' | ' | ' | ' | ' |
Related Party Transaction, Amounts of Transaction | ' | ' | ' | ' | 52,000 | 60,000 | ' |
Accounts Payable, Related Parties, Current | ' | ' | ' | ' | 1,000 | ' | ' |
Reduction In Compensation To Related Parties | ' | ' | ' | ' | $48,000 | ' | ' |
Compensation Reduction Percentage | ' | ' | ' | ' | 20.00% | ' | ' |
SUBSEQUENT_EVENTS_Details_Text
SUBSEQUENT EVENTS (Details Textual) (Subsequent Event [Member]) | 12 Months Ended |
Dec. 31, 2013 | |
Subsequent Event [Member] | ' |
Restricted Shars Issued For Payment Of Non Accountable Expenses | 208,333 |
SEGMENT_AND_GEOGRAPHIC_INFORMA2
SEGMENT AND GEOGRAPHIC INFORMATION (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Segment Reporting Information [Line Items] | ' | ' |
Net sales | $8,894,000 | $9,343,000 |
United States [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net sales | 8,158,000 | 8,405,000 |
North America (not domestic) [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net sales | 197,000 | 430,000 |
Europe [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net sales | 174,000 | 343,000 |
Asia/Pacific Rim [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net sales | 66,000 | 50,000 |
South America [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net sales | 297,000 | 115,000 |
Africa [Member] | ' | ' |
Segment Reporting Information [Line Items] | ' | ' |
Net sales | $2,000 | $0 |